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Abstract 
ABSTRACT 
Inhibitors of Activator Protein-1 (AP-1)~ a collective term referring to dimeric 
transcription factors involved in mediating long term responses to signals that 
regulate growth control and development~ were designed and synthesised in this 
study. Truncated peptide sequences of 5-7 residues containing the highly conserved 
tri-amino acid sequence KCR found in the DNA binding domains of the AP-1 family 
of proteins were attached to mono-substituted anthraquinones through various amino 
acid type linkers. It was envisaged that these intercalator-linked peptides would have 
the advantage of high DNA binding with some sequence selectivity. 
The peptides (l:ARCKA; 2:AKCRA; 3:AKSRA; 4:AKCRNA; 5:AKCRKA; 
6:AKCRNKA; 7:AKCRKRA; 8:AAKCRAA) were synthesised using solid phase 
peptide synthesis. The amino acid type linkers were attached to 1-
chloroanthraquinone Via a nucleophilic displacement reaction and subsequently 
coupled to the N-terminus of the resin bound peptides using PyBOP. 
Characterisation of the peptides and the intercalator-linked peptides was conducted 
using HPLC~ MALDI-MS and 2D-NMR spectroscopy. Biophysical analysis of the 
peptide conjugates with DNA using fluorimetry and thermal denaturation studies 
indicated that the AP-I inhibitors were weak intercalators of DNA and suggested that 
DNA binding of these intercalator-linked peptides was govemed~ in principle, by the 
peptidic moiety. Electrophoretic mobility shift assays of the peptides and their 
respective conjugates demonstrated that the latter were more effective in displacing 
the AP-1 protein compared to the peptide moieties alone. These assays also showed 
that the peptides and conjugates bearing the sequences AKCRNA (peptide 4) and 
AKCRKRA (peptide 7) were particularly effective in inhibiting the AP-1 protein 
binding. Peptides 4 and 7 were also shown to possess an intrinsic propensity to form 
helical structures upon transfer to hydrophobic environments and also to interact with 
the DNA AP-I consensus sequence more favourably compared to peptides 1. 2. 3. 5, 
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Cancer is a complex family of diseases that results from the breakdown or 
suppression of the mechanisms responsible for normal cellular growth and 
development. The relentless unchecked division of cancer cells results in the 
formation of malignant tumours that compress and crowd out surrounding healthy 
tissue. As tumour growth progresses, angiogenesis takes place, where upon a 
tumour vasculature system develops to provide oxygen and other metabolites to 
nourish the rapidly expanding cell mass [1,2]. The vasculature system, however 
is often abnormal or poorly developed which means that the blood flow and rates 
of diffusion to these tumours is not uniform. This results in insufficient nutrient 
delivery to the tumour cells, which become starved of oxygen and metabolites and 
therefore become necrotic or hypoxic [3]. 
1.2 Hypoxic Tumours 
Oxygen deficient (i.e. hypoxic) cells represent a limiting factor for the therapeutic 
treatment of solid tumours (figure 1) due to increased radiation and cytotoxic 
chemotherapy resistance relative to oxygenated tissues [4]. These cells are 
approximately three times less sensitive to X-irradiation, a condition resulting 
from the diminished formation and altered half times of reactive oxygen radicals 
in a hypoxic environment [5,6]. The same is true of cytotoxic agents that require 
the formation of radicals within the cell. Resistance to anticancer agents in solid 
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tumours is also a direct result of decreasing transport of drugs to the cells as they 
become increasingly distant from operative vasculature systems as tumour grow1h 
progresses (7). Solid tumours, in particular those that are under oxidative stress 
pose a serious problem in the effective treatment of cancer [8). 




- Hypoxic CelI~ 
Figure J Schematic Representation of a Hypoxic Tumour (the area in black 
represents acute hypoxia) {9} 
Another important feature of hypoxic tumours is their ability to continue growing 
in the presence of very little or no oxygen. This observation has been attributed to 
the fact that the affmity of various transcription factors involved in stress 
responses for their cognate DNA sequences is dependent on the redox state of 
specific cysteine (Cys (C)) residues found in the DNA binding domains of these 
proteins [10.11). Such transcription factors include the Myb. NF -ill proteins and 
in particular the activator protein-l (AP-l ). a ll of which become active under 
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reducing conditions, including hypoxia, thus permitting transcription and hence 
tumour growth [12,13]. The activation of the AP-1 under reducing conditions and 
its role in oncogenesis is discussed in section 1.3.4. 
1.3 Activator Protein-l 
AP-1 is a collective term referring to dimeric transcription factors composed of 
subunits from the fos, jun and activating transcription factor (ATF) multigene 
families. The fos family contains four proteins (c-fos, fos-B, fra-1, fra-2) while 
the jun and ATF families are each composed of three (c-jun, jun-B, jun-D and 
ATF-2, ATF3/LRF1, B-ATF respectively) [14]. The AP-1 consists of 
homodimers and heterodimers of the fos, jun and ATF proteins which have the 
common property of interacting with the DNA sequence, TGACTCA, known as 
the AP-1 binding site or the 12-0-tetradecanoylphorbol-13-acetate (TPA) 
responsive element (TRE) and also to certain closely related variants such as the 
TGACTGCA sequence, referred to as the cyclic adenosine monophosphate 
(cAMP) response element (CRE) [10,12]. These transcription factors are 
involved in the activation of several genes including those coding for 
metallothionein IIA, collagenase and stromelysin [10]. There are also binding 
sites for the AP-1 in the simian virus 40 enhancer regions as well as in numerous 
other cellular genes including the DT -diaphorase and glutathione S-transferase 
genes [15,16]. The AP-1 is therefore a sequence specific protein which is 
involved in mediating long-term responses to signals that regulate growth control 
and development [11,12]. 
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Fos and jun, like the ATFICREB and GCN4 proteins are members of the bZip 
family of sequence specific dimeric DNA binding proteins. The members of this 
family share a common structural motif, but differ in their ability to differentiate 
DNA target sites [17]. The term 'bZip ' refers to the amino acid sequences of two 
independently acting sub-regions (figure 2) of the DNA binding domain. One 
region facilitates dimer formation and the other contacts DNA. The dimer-
forming region, termed the leucine zipper (Zip) is characterised by a pattern of 
leucine (Leu) residues repeating every seventh amino acid and is responsible for 
mediating protein-protein interactions [18]. At the NH2-terminal of the leucine 
zipper region there is a basic (b) region which is composed of highly basic and 
hydrophobic residues. This domain is essential for sequence specific DNA 
binding. The two regions are discussed in detail below. It is important to note 
that the sequence of the leucine repeats as well as that of the basic region, is 
highly conserved within the fos and jun families [12]. 
BASIC MOTIF LEUCINE ZIPPER 
JlINB E DQ E R I KVERKRLRNRLAAT KC R KRKL E R I A RL EDKVKTLKAENAGLSSAAGLLREQ 
.WN ESQE RI KAERKRMRNRI AAS KC R KRKLERI ARL EEKVKTLKAQNSELASTANMLREQ 
GCN~ VP ESS DPAALKRARNT E AAR R S R A RKL Q R MKQLEDKVEELLSKNYHLENEVARLKKK 
FOS S P FEEE KRRI RR E RNKMAA AKC R NRRR E LTDTLQA ET DQLEDEKS A LQ TE I AN LLK E 
FRAI S P FEEE RRRVRR E R NKLAAA KC R N RRK E LTDFLQAETDKLED E KSGLQR E I EE LQKQ 
Figure 2 The 'Basic motif' and 'Leucine repeat' of the Fos, Jun and GCN4 
Proteins 1191 
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1.3.1 DNA Binding of Fos-Jun Heterodimers 
Although no direct structural information or data regarding the interaction of the 
binding domain of the AP-1 proteins with DNA is available, two closely related 
models have been proposed. The structural features of these models, that is the 
'induced helical fork' and the 'scissors grip' models are similar in principle [20-
22]. In both cases the basic region-leucine zipper is shaped like a Y. The parallel 
leucine zipper region forms the stem of Y and the basic regions form a-helices 
that can be considered as the 'arms' of the Y. In both models the N-terminal 
region of the two-fold symmetric leucine zipper fits over the centre of the DNA 
binding site, and the helices from the basic region extend in opposite directions 
along the major grooves of the DNA, figure 3. The two models differ however in 
their predictions regarding the interaction of the helices of the basic domains with 
DNA. The a-helix from the basic region is believed to be straight, projecting 
away from the DNA after contacting three or four base pairs in the induced helical 
fork model [21], however the scissors grip model predicts that this helix is kinked, 







Figure 3 Schematic Representation of the DNA AP-l Interaction 
1.3.2 The Leucine Zipper 
The leucine zipper is essential for the specific dimerisation between the fos and 
jun proteins. This domain is composed of two a-helices that are approximately 30 
amino acids long and are characterised by a heptad repeat of Leu residues [23]. 
These a-helices interact in a parallel orientation to form a structure reminiscent of 
a coiled coil [22]. The side-chains of the Leu residues from one a-helix 
interdigitate with those from a second, thus forming strong hydrophobic 
interactions that mediate dimerisation [24]. It seems that this parallel interaction 
of the dimerisation (or leucine zipper) domains serve to juxtapose the basic 
regions (binding domains) of the fos and jun proteins, each of which is therefore 
6 
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able to contact both strands of the AP-1 binding site [25]. Only as the dimer is the 
strong and sequence selective binding of the AP-1 protein achieved [25]. 
lun proteins by themselves can bind as homodimers to the AP-1 and CRE 
enhancer elements in DNA, fos alone however, is unable to dimerise under 
physiological conditions and hence incapable of binding either site [26]. The 
heterodimeric protein i.e. fos-jun binds the DNA AP-1 and CRE sites with a 
much greater affinity than the jun homodimers. This observation may either be 
explained by the formation of more stable fos-jun dimers compared with the jun-
j un dimers or by the high density of basic residues found in the fos component 
which makes the heterodimer more electrostatically compatible with the 
backbone of DNA [27] which is negatively charged. 
1.3.3 The Basic Region 
The basic region consists of a 16 amino acid residue consensus which is required 
for sequence-specific DNA binding by the AP-1 transcription factor [28]. This 
domain is rich in arginines (Arg (K)) and lysines (Lys (L)), but also contains other 
residues that are conserved throughout the bZip proteins. This region binds to 
non-specific DNA sequences in a partially helical conformation thus allowing the 
protein to effectively "search' the DNA for its recognition sequence i.e. the AP-1 
site. Once this sequence has been recognised the basic region becomes 
completely helical and forms a number of H-bonds and van der Waals contacts 
with the nucleotide bases found in the major groove of DNA. 
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1.3.4 AP-1 Activation 
DNA binding of the AP-I is actually modulated by the redox state of a single 
conserved Cys residue found in the basic DNA binding domains of the fos andjun 
proteins [29]. This Cys residue, which is mutated to serine (Ser (S)) in the 
oncogenic homologs of c-fos and c-jun, i.e. v-fos and v-jun respectively, is 
flanked by basic amino acids and is located in a highly conserved triamino acid 
sequence i.e. Lys-Cys-Arg (KCR). This particular sequence is found among all of 
the fos and jun related proteins and in several of the ATF/CREB proteins [11], 
figure 4. A similar motif is also present in the DNA binding domains of the Myb 
(KQCR) and NF-KB (KICR) proteins, both of which bind DNA in a redox 
dependent manner [30]. 
The reactive nature of the Cys residue which is enhanced by the local basic 
environment makes it readily susceptible to oxidation and thus an attractive 
candidate for regulation by a redox mechanism [29]. Thiol reduction of this 
critical Cys residue either by chemical reducing agents or nuclear extracts (e.g. 
redox factor nuclear protein) generates a free sulfhydryl group which permits 
DNA binding of the AP-I transcription factor and hence activates transcription 
and cell growth [11]. Oxidation of this residue, however renders the AP-I 
inactive by converting the Cys residue to a state that is not permissive for DNA 
binding and thus prevents transcription. Under such conditions the Cys residue is 
transformed to either one of two reversible products i.e. a sulfenic (RSOH) or a 
sulfinic (RS02H) acid, as opposed to the irreversibly oxidised form suI phonic acid 
8 
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acid (RS03H) and the more common reversible disulphide oxidation product [29]. 
Substitution of this critical Cys residue in the DNA binding domains of the fos 
and jun proteins with Ser, however results in increased DNA binding activity and 
loss of redox control [5]. 
Fos R R E R N K M A A A K C R N R R R E L T 
FosB R R E R N K L A A A K C R N R R R E L T 
Fral R R E R N K L A A A K C R N R R K E L T 
Fra2 R R E R N K L A A A K C R N R R R E L T 
Jun K R M R N R I A A S K C R K R K L E R I 
JunB K R L R N R L A A T K C R K R K L E R 1 
JunD K R L R N R I A A S K C R K R K L E R I 
eRE R L M K N R E A A R E C R R K K K E Y V 
B R L M K N R E - A R E C R R K K K E Y V 
ATFl F L E R N R A A A S R C R Q K R K V W V 
ATF2 R R E R N K I A A A K C R N K K K E K T 
ATF3 
Figure 4 Sequence Alignment of the Basic Motifs of the Fos, Jun and ATF 
Proteins {11 J 
The exact mechanism responsible for redox control of DNA binding activity of 
the AP-l transcription factor is not yet clearly understood. However a stimulatory 
factor present in mammalian nuclear extracts has been shown to stimulate the 
binding of the fos and jun proteins. This bifunctional protein, designated redox 
factor (Ref-1), in the absence of sulphydryl reducing agents maintains the reduced 
state of the Cys residue required for DNA binding of the AP-1 protein [5,29]. 
Ref-1 has also been shown to possess an endonuclease activity involved in the 
repair of DNA [11,29]. This protein enhances the affmity of the fos and jun 
9 
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proteins for DNA indirectly and does not participate in the DNA-protein 
interaction [29]. Interestingly, Ref-1 itself is subject to redox control and its 
activity is augmented by thioredoxin, thus suggesting that a redox cascade could 
be invo lved in AP -1 regulation [11 ,25]. 
1.4 AP-l Inhibition 
The implication of various members of the bZip family of eukaryotic transcription 
factors and in particular the AP-1 in the induction of certain types of cancer has 
aroused a great deal of interest in these proteins. Although the function of these 
proteins in tumour growth is well documented no structural data on the interaction 
of the AP-1 with its cognate DNA sequence is yet available. However the 
solution structure of the yeast transcription factor GCN4 which shares a 
homologous DNA binding domain to the fos and jun proteins has been resolved 
and is therefore used in the study of the AP-1 and its interactions with DNA. The 
crystal structure of GCN4 complexed with the AP-1 oligonucleotide binding 
sequence has also been resolved [17], and is better described by the induced 
helical fork model (figure 5). 
10 
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Figure 5 A Computer Model of GCN4 Complexed with the DNA AP-1 
Consensus Sequence 117} 
II 
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The redox control of the AP-1 transcription factor plays an important role in both 
cell proliferation and malignant transformation, the latter of which is more likely 
to occur under conditions of oxidative stress where the tumour cells have very 
little or no oxygen [13]. The low level of oxygen in these tumour cells thus 
maintains the Cys residue of the AP-1 in a reduced state which permits DNA 
binding of the protein and hence activates transcription and tumour growth. It is 
possible to conceive three general methods of inhibiting the AP-1, firstly to 
prevent dimerisation of the fos and jun proteins, secondly to provide an agent that 
binds to the protein dimer and hence prevents it from binding to DNA and thirdly 
to design a drug that binds the DNA AP-1 site and thus prevents DNA binding of 
the protein. Since DNA is arguably the best characterised target in cancer 
therapy, with a number of clinical agents already established with strong DNA 
binding moieties, it is natural to consider an approach based on method three in 
the first instance, preventing the AP-1 protein from activating transcription. The 
loss of transcription of important genes responsible for tumour cell survival and 
division would provide a novel and selective route for the treatment of cancer. 
12 
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1.5 DNA Binding Agents 
1.5.1 Intercalation 
The process of intercalation entails the insertion of a flat aromatic chromophore 
between the base pairs of DNA [31-34]. In order to accommodate the 
intercalating molecule, the duplex unwinds in the region of intercalation, thus 
increasing the separation between the planes of the base pairs (figure 6). This 
results in both the lengthening and distorting of the double helix which affects its 
interaction with DNA associated enzymes and nuclear proteins [33]. Intercalation 
therefore interferes with the role of DNA as an effective template for DNA and 




Figure 6 (a) Native DNA (b) Intercalated DNA [34J 
1.5.2 Natural Hybrid Peptides 
The naturally occurring peptide antibiotics such as the actinomycins and 
echinomycins (figure 7) are potent cytotoxic agents. These anti-tumour 
antibiotics, which are selective inhibitors of DNA directed RNA synthesis, are 
characterised by chromophoric intercalating and bis-intercalating groups attached 
to peptidic moieties [35]. The former, i.e. the intercalating group, facilitates DNA 
binding by the mode of intercalation, where as the latter provides nucleotide 
sequence specificity. Considering the effect of the intercalating chromophore on 
the DNA binding of nuclear proteins, many intercalating agents such as the anti-
14 
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tumour antibiotics, actinomycin and echinomycin can be thought of as naturally 
occurring transcription factor inhibitors. 
Echinomycin 
Actinomycin 
Figure 7 Natural Occurring Anti-tumour Antibiotics 
1.6 Aims of this Study 
The aim of this project is to design, synthesise and analyse a number of potential 
redox sensitive transcription factor inhibitors. These should be able to compete 
with AP-l for its cognate DNA sequence. The inhibitor designed must therefore 
be specific for the AP-l DNA binding site, redox active and selective under 
oxidative stress or hypoxic conditions. 
15 
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The design principle of the naturally occurrmg peptide antibiotics has been 
adopted as a paradigm for the potential AP-l transcription factor inhibitors. It is 
anticipated that the specificity of these drugs for the AP-l site can be achieved by 
designing peptides that mimic the DNA binding domains of the AP-l 
transcription factor. A redox switch will ensure that the inhibitors are selective 
under oxidative stress/hypoxic conditions and the incorporation of an intercalating 
moiety will facilitate initial DNA binding and hence nuclear accumulation of 
these agents. 
1.6.1 A Potential Hypoxia-Selective Anti-Tumour Agent 
Taking into consideration the information obtained from previous studies and the 
factors necessary for the binding of the fos-jun heterodimer to the DNA AP-l 
binding site, the structure shown in figure 8 has been proposed as an example of a 
potential AP-l transcription factor inhibitor. 
16 
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NH2r l H 
N H? NH 
( ~H~l3 fH (7H2l2 
o CH3 0 CHI 0 CHI 0 CH, 0 CH:; 0 II I II I - II I - II I - II I II 
o N H(CH2)3C-N H -CH -CN H -CH -CNH -CH -CN H -CH -CN H -CH - C- X Y Ala L~s C~s Arg Ala 




x = OH orNH2 
Figure 8 A Potential AP-J Transcription Factor Inhibitor 
The specificity of this anti-tumour agent will be provided by the peptide moiety. 
the sequence of which has been based on the factors necessary for the binding of 
the fos-jun heterodimer to the DNA AP-l site. It is anticipated that DNA binding 
of this agent will compete with the binding of the AP-l transcription factor , and 
therefore prevent transcription and tumour growth. The overall objectives of this 
project have been sunm1arised below: 
• Synthesis of the proposed structure (figure 8) and its analogues using 
various peptidic sequences (principally bearing the KCR motif). linker 
groups and chromophores. 
17 
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• Attempt the synthesis of an a-helical constrained peptide bearing the 
KCR motif and the determination of its effect on the DNA binding of 
the drug. 
• Biophysical evaluation of the peptides and peptide conjugates to assess 
relative binding affmities to DNA and selective inhibition of AP-l 
protein binding to DNA. 
• Structural evaluation of the drugs synthesised using Circular Dichroism 
(CD), 2D-Nuclear Magnetic Resonance (NMR) and molecular 
modelling techniques to establish the secondary structure adopted by the 
peptides and their respective conjugates. 
• Conduct theoretical studies on the peptidelDNA complexes usmg 




The following chapter provides a background to the techniques employed in 
peptide synthesis and to the methods used to evaluate. both biologically and 
structurally, the transcription factor inhibitors synthesised in this study. The 
results obtained from the synthesis and evaluation of the inhibitors are presented 
and discussed in chapters 3 and 4 respectively. 
2.1 Peptide Synthesis - An Overview 
Peptide synthesis involves a series of protection, deprotection and coupling 
reactions. The coupling or amide bond forming reaction essentially involves the 







- OH +L:HNH T~C­




Rand RI = Amino acid side-chains 




a -Amino acids, although chemically varied, all contain an amino group. carboxyl 
group and a distinctive R (side-chain) group with the exception of glycine. all of 
which are attached to the single a-carbon atom [36]. Both the amino and 
carboxyl groups are reactive centres that behave as nucleophilic and electrophilic 
entities respectively. Thus in order to prevent polycondensations. i.e. the 
formation of higher polymers, it is necessary to block those functional groups that 
are not required to participate in the peptide bond forming reaction [37] . That is 
to say that protecting groups are required for the amino function of the amino acid 
to be activated (i.e. the carboxyl component) and the carboxyl group of the amino 
acid to be acylated (i.e. the amino component),figure 10. 





X-NH-CHR-CO- NH- CHR'-COO-Y 
X and Yare protecting groups of the a- amino and carboxyl groups respectively. 
Figure 10 Amino Acid Protection 
These protecting groups not only suppress the reactivity of the functional groups 
but also destroy the zwitterionic character of amino acids when in solution. in 
which the amino and carboxyl groups become protonated and deproto nated 
20 
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respectively. It is essential to prevent the formation of zwitterions (figure 11) as 
this diminishes the solubility and reactivity of the residue. 
Figure 11 The Internal Salt or Zwitterion 
Elongation of the dipeptide can be achieved by simply removing one of the 
protecting groups, conventionally the amino protecting group and then coupling 
with a carboxyl-activated amino acid [38]. It is essential that the protecting group 
of one functionality i.e. the amino group, can be selectively removed under 
conditions that do not effect the masking of the other (carboxyl function) and vice 
versa. It is also important that the peptide bond is not cleaved during the process 
of deprotection. Protection of the functional groups present in the side-chains of 
many amino acid residues, such as Arg and Lys, is also necessary as these groups 
can also participate in the peptide bond forming reaction. These groups require 
orthogonal protection for at least one of the a-functions, which means therefore 
that selective deprotection can be achieved [37]. For instance the a- and E-aminO 
groups ofLys may be masked with acid (e.g. t-butyloxycarbonyl group (Boc)) and 
base (e.g. 9-fluorenylmethoxycarbonyl group (Fmoc)) labile protecting groups 
respectively. This essentially means that the a-amino function can be selectively 
21 
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deprotected without effecting the protecting group used to mask the £-amino 











Figure 12 Orthogonal Protection of the Lys Residue 
2.1.2 Amino and Carboxyl Protecting Groups 
o 
Protecting groups employed to mask the amino function of a residue are required 
to suppress both the basic nature and nucleophilic reactivity of the nitrogen atom . 
Thi s is achieved by either draining its electron density a\\lay into an appropriate 
substituent (i. e. delocalisation of the lone pair of electrons) or by concealing it 
behind a screen of stenc hindrance [38] . Protection of the amino group can be 
accompli shed by simply transforming it to its corresponding amide. Howe\·er. 
although this method of protection renders the amino function inert. the resultant 
amidic bond to the protecting group may not be readily distinguished from the 
amidic backbone of the peptide. Under these circumstances, deprotection may 
result in peptide cleavage. Furthermore, the electron withdra\ying nature of the 
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amide group enhances the acidity of the a-proton and therefore results ill 
racemisation. 
The protecting groups more commonly employed to mask the amino function are 
carbamates. They are related to the amide group and include the Boc and Fmoc 
groups [37,39]. These particular masking groups are more desirable than the 
amides as the carbonyl groups are less electron withdrawing. This is due to the 
delocalisation of a lone pair of electrons from the oxygen into the carbonyl group, 
lowering the electron demand on the protected nitrogen. Additionally. this 
electron donation by the oxygen atom renders the carbamate carbonyl less 
susceptible to nucleophilic attack [37]. The final advantage of carbamate 
protecting groups is that they can be deprotected under conditions that relate to the 
hydrolysis of the ester component of the ROCONHR1 moiety. Subsequent 
spontaneous decomposition of the resultant carbamic acid reveals the free amino 
group. 
Although the carboxyl function of an amino acid residue is less nucleophilic than 
the amino group with respect to acylation, it still requires protection. This not 
only aids solubility of the peptide in organic solvents but also allows 
unambiguous activation in the presence of a coupling reagent (i.e. only the 
unprotected carboxyl group is activated). The usual means of carboxyl protection 
is esterification, the most common groups being the alkyl esters such as the 
methyl and ethyl esters. Esters are also commonly employed in solid phase 
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peptide synthesis which often involves the attachment of the C-terminal amino 
acid residue to the resin through an ester linkage, thus providing both an 
attachment point and C-terminal protection. Typically such esters are substituted 
benzyl esters which are cleaved by acidolysis to yield the desired peptide 
terminus. In the context of this work, the side chains of Arg, Cys, Lys and Ser all 
required protection, the protecting groups to be employed in this synthesis are 
described in table 1. 








































C02H 2o/t) Hydrazine 
Table 1 (Continued) Amino Acid Protecting Groups 
Protecting Group Abbreviation Structure Function ()eprotection 
Protected Conditions 
Methyl Ester OMe -0('11, C0211 ROIl/Olr 
Pentafluorophenyl Ester Opfp F~§)~F Ji 
I· I' 
C0211 1(% TFA 
('II, ('II, 
2,2,5,7 ,8-Penta methyl- Pmc 
,II. " r)~ ~ NII2 TFA chroman-6-su Iphonyl (,",X ('II, 
ell, 
2,2,4,6,7- Pbf CII>(JQrC::. NII2 TFA Pentamethyldihydrobenzo-
furan-5-sulfonyl 








In order to convert the carboxyl group of an amino acid into an acylating agent. 
the OR group must be replaced with, or activated by an electron withdrawing 
group [38]. This is required to increase the electrophilicity of the carbon of the 
carboxyl group, and provide an improved leaving group, hence greatly facilitating 
nucleophilic attack by the nitrogen of the amino component. Furthermore, as 
shown in the reaction mechanism in figure 13, the electron-withdrawing group 
should ideally facilitate deprotonation of the quaternised nitrogen. This favours 
the production of the product from the intermediate over decomposition back to 
the starting materials. 
x = Activating group; R, Rl = Amino acid side-chains 
Figure 13 Carboxyl Activation 
Activation can be a two step process i.e. initial carboxyl over-activation which is 
then followed by substitution with a nucleophile that provides a secondary 
activating function of lower reactivity [38]. Two of the most commonly 
employed coupling agents in peptide synthesis are l-ethyl-3-(3-dimethylamino-
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propy l)carbodiimide (EDC) and benzotriazole-l-yl-oxy-tris-pyrrolidino-
phosphonium hexafluorophosphate (PyBOP) (figure 14), the former of which is 
often used in solution phase synthesis and the latter in solid phase peptide 
synthesis (SPPS). The use of coupling agents are advantageous as they can be 
added to a mixture of the carboxyl and amino components, thus allowing 
activation and coupling to proceed concurrently. These coupling agents promote 
amide bond formation by reacting with the carboxyl group of the amino acid and 





/.N, + ~ 
N'" N-O-P N0 
o PyBOP 
Figure 14 Coupling Agents, EDC and PyBOP 
3 
All amino acids (except for glycine) are optically active and hence prone to 
racemisation during the coupling process. Increased electrophilicity of the 
carbonyl carbon by coupling agents leads to an increase in the acidic nature of the 
a-hydrogen thus increasing the possibility of racemisation [37,38]. the most 
important mechanism of which involves the formation of activated acylamino 
acids as shown below: 
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Racemization 
H II 0 0 
R-C-C H II H II 
mf 'X ::;;;jjj_==_~R JC-tiC1_-HX _R JC-CI 
\ ~..... ~ 
C=O C 6~H c-o 
~, I I 
R' R' [A] 
Racemization of azlactone [A] results from the abstraction of the acidic proton 
from the chiral centre, the ease of which is due to the resonance stabilisation of 
the carbanion generated: 
o 0- 0 
- II I II 
R-C-C R-C=C R-C-C 
/ I / I _Nh,'1_1 N "'~f-----I"~ N -""---'--
~ ~ 
C-O C-O C-O 
I I I 
R' R' R' 
o 
I 
R-C;=:C / ' I N<-, ''----C-O 
I 
R' 
In order to prevent racemization an auxiliary nucleophile such as N-
hydroxybenzotriazole (HOBt) is required. HOBt (figure 15) is termed an 
auxiliary nucleophile as it destroys the highly activated intermediates and thus 
remits proton abstraction from the chiral carbon atom preserving chiral purity 
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[37,38]. The addition of such a nucleophile is prerequisite in reactions in which 
carbodiimides such as EDC are employed, however where PyBOP is used, such a 
reagent is not required as HOBt is generated in situ, see section 3.2.3. 
Figure 15 N-HydroxybenzotriazoJe 
2.1.4 Solution Phase Peptide Synthesis 
Whilst useful for the preparation of large quantities of short peptides, solution 
phase synthesis is not without inherent difficulties. It employs techniques of 
solvent extraction, filtration, evaporation, recrystallisation and possibly 
chromatography, all of which are both time consuming and lead to loss of 
product. The total number of steps involved in the synthesis of even moderately 
sized peptides can therefore be quite substantial. Furthermore, purification by 
recrystallisation and chromatography become increasingly difficult as the peptide 
chain length increases. The problems encountered with peptide purification and 
the low yields make this a less favourable method of peptide synthesis. 
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2.1.5 Solid Phase Peptide Synthesis 
The fundamental premise of Solid Phase Peptide Synthesis (SPPS) is the 
sequential addition ofN-a protected amino acid residues to a peptide linked to an 
insoluble polymeric support [40]. The 'growing' peptide sequence remains 
attached to the support or resin via a linker, through its C-terminus throughout the 
synthesis, allowing unreacted reagents and by-products to be removed by simple 
washing procedures. 
There are two techniques employed in SPPS, namely, 'Batchwise' and 
'Continuous flow' synthesis. In the former technique the synthesis is carried out 
in a filter reaction vessel, which allows the support to be filtered and resolvated at 
the end of each stage. However, in the latter, the resin remains solvated 
throughout the synthesis and is contained in a column through which the reagents 
and solvents are pumped continuously [41]. Generally only the Fmoc strategy is 
used with the continuous flow method, however both Fmoc and Boc chemistry 
can be used in batch synthesis. In both cases, the reagents can be added and 
removed under manual or computer control. 
SPPS essentially involves the reversible attachment of the first amino acid residue 
to a solid support, which is then followed by a repeated cycle which involves 
deprotection (i.e. liberation of the free amino group) and acylation with the next 
N-a protected residue. The general scheme of SPPS is shown in figure 16. The 
resin and its attached peptide is washed thoroughly at the end of each step with an 
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appropriate solvent, this removes any by-products formed and any unreacted 
reagents remaining in the reaction vesse l. This cycle is repeated until the des ired 
peptide sequence is achieved. The product is then iso lated by treating the support 
with a strong acid such as hydrogen fluoride or trifluoroacetic ac id (TF A) . which 
allows the simultaneous cleavage of the peptide fro m the resin and the removal of 
any acid-labile protecting groups present in the side-chains of the amino acid 
residues [41]. 
X-NH-CHR(P)-COOH i RESIN 
X-NH-CHR(P)-COO-RESIN 
De protection 1 
NH2-CHR(P)-COO-RESIN 
Amidation 1 
X-NH -CHR'( P' }-COOH 
X_NH_CHR'(P~)-CO-NH- CHR(P)-COO-RESIN 
Cleavage and Dcproteelion 1 
NH2 -CHR'-CO-NH-CHR-COOH 
Repeat De protection 
a nd Amidation 
. I '" X= N-a protectmg group; P and P = SIde cham protectmg groups 
Figure 16 A General SPPS Protocol 
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SPPS not only avoids the purification of peptide intermediates but it also 
minimises the physical loss of the peptide product, as it is retained in the same 
vessel throughout the synthesis. The relative ease with which soluble reagents are 
removed is also advantageous as it allows an excess of the reagents to be used. 
and therefore facilitates a high product yield. 
The main disadvantage associated with SPPS is that the peptide intermediates 
cannot be purified and that possibilities for their characterisation are limited. The 
analytical methods often employed in solution phase peptide synthesis are not 
always practical in SPPS, for example spectroscopic study is often impeded by the 
presence of the polymeric resin support [41]. This can be rather problematic in 
the detection of truncated sequences or prematurely terminated chains i.e. 
deficient peptides go undetected and therefore create further problems in the 
purification of the [mal product. The formation of such undesirable products 
however, can be avoided by monitoring the reactions to establish the 
completeness of acylation and to ensure that deprotection of the a-amino group is 
complete. The former can be achieved by performing a Kaiser test [42] which 
determines the presence of unreacted primary amino groups, therefore indicating 
the completion of acylation. Deprotection, however, can be monitored by 
employing an in-line Ultra Violet (UV) spectrophotometer which detects the 
cleaved Fmoc derivative dibenzofulvene (see section 3.2.4.1). this however is 
only possible in continuous flow synthesis. 
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Another major problem associated with SPPS is peptide-chain aggregation, which 
is due to either hydrophobic interactions or interchain hydrogen bonding. This 
typically occurs between 5-15 residues from the C-terminus and can lead to 
incomplete coupling and deprotection [40,43]. However, peptide chain 
aggregation can be avoided by the addition of soluble ureas to the acylation 
reaction, which disrupt hydrogen bonding and can lead to increased coupling 
yields. Despite the problems associated with SPPS, this method is still preferred 
and hence commonly employed. 
2.1.6 Protein Structure 
Many of the bonds in a polypeptide/protein chain allow free rotation of the atoms 
giving the peptide backbone great flexibility. This therefore means that the 
polypeptide is able to apparently adopt an almost unlimited number of 
conformations, however this is dependent on its primary structure [44]. The 
conformation anticipated in the peptides employed in this study is the alpha helix. 
This secondary structural motif (figure 17) is generated when the backbone turns 
regularly about itself to make a rigid cylinder in which each residues' carbonyl 
group forms a hydrogen bond with the amide NH group of the residue four amino 
acids along the chain. 
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Figure 17 An Alpha Helix [44} 
Investigations of the chemical and physical properties of isolated helices have 
long been hampered by the inability of most linear peptides to sustain an a-helical 
conformation in aqueous solution. It is because of this that several methods for 
constraining short peptides to an a -helical conformation have been developed. 
Such approaches or methods have involved the incorporation of salt bridges [-+5]. 
modification of the solvent [46] and more favourably the formation of di sulphide 
[47A8] and amide bridges [49.50]. The method to be adopted in thi s synthesis is 
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one described by Phelan and co-workers [50] in which glutamic ac id residues at 
positions i and i+ 7 are bridged together with an alkanediamine chain. figure 18 . 
In the fIrst instance attempts at constraining only a single peptide were made using 
this method as at this stage it was not known whether or not the alkanediamine 
bridge would mask the binding moieties of the peptide and hence prevent/hinder 
its interaction with the DNA AP- l site . Further details of this approach will be 
discussed in section 3.7 . 
I i ," I 
O~yNH NHyO 
NH2-Glu-X-X-X-X-X-X-Glu-CO-Y 
n = Number of methylene groups; X = Amino acid residues ; Y = NH or OH 
Figure 18 Constrained Peptide 
2.2 Biophysical Studies 
Spectroscopic studies, together with electrophoretic mobility shift assays (EMSA) 
were used to ascertain information regarding the biological activity of DNA 
binding ligands. The former can be used to determine the mode of binding and 
affinity of a drug for DNA. whereas the latter is employed to establish the 
se lectivit y and specificity of a drug for a particular DNA sequence. 
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2.2.1 DNA Binding Studies Using Spectroscopic Methods 
Plumbridge and Brown [51] were amongst the first to show that a combination of 
spectroscopic and fluorescence techniques can be used to positively identify the 
interactions of synthetic intercalators with nucleic acids. Both the nature of 
binding and the affinity of a drug for DNA can be determined using these 
methods. It is essential, however, that the techniques employed distinguish the 
intercalative mode of binding from other modes and also allow the determination 
of the affinity of the drug when intercalation is shown. Consequently the methods 
used in assessing DNA binding fall into two categories. In the first group of 
methods the results generated affords information on the nature of binding. The 
second group of methods, however, is of a quantitative nature and provides 
information on the binding affinity of a drug for DNA. The methods used can 
further be subdivided into those that monitor spectroscopic changes in the 
properties of the drug and secondly those that monitor changes in the physical 
properties of DNA. 
2.2.2 Spectroscopic Studies 
On binding of a drug to DNA there IS a spectral change in the absorption 
characteristics and fluorescence spectrum. These spectroscopic methods are 
applicable to the examination of intercalating drugs since the "-max value for 
intercalating drugs (~400nm) are at a longer wavelength than the absorption due 
to nucleic acids (260nm) [51,52]. Spectrophotometric and fluorescence methods 
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can therefore be employed to determine the nature of binding and the affmity of a 
drug for DNA. 
Typically the absorption spectrum of a drug upon intercalating into DNA is 
shifted to a longer wavelength (bathochromic shift) and the maximum absorptivity 
is decreased (hypochromism) [53]. The combination of bathochromic shift and 
hypochromism make it likely that the spectra of free and bound drug will cross at 
least one point. Thus when the spectra of solutions containing a fIxed 
concentration of drug and varying concentrations of DNA (from 0 to 10:1 of DNA 
to drug) are superimposed then all the spectra will pass through this point, which 
is termed an isosbestic point. This however will only occur if there is a single 
spectroscopically distinct bound form of the drug molecule in addition to the free 
drug. The appearance of an isosbestic point is therefore essential if such spectra 
are to be used to determine the affinity of the drug for DNA. 
Consequently when an isosbestic point is observed the affmity constant (K) for the 
binding reaction and the number of sites per DNA phosphorous (n) can be 
determined by the method of spectrophotometric titration [32,51]. This method is 
based on the assumption that the interaction of a drug with DNA involves a 
reversible dynamic equilibrium, which can be represented as follows: 
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Drug + DNA :;:-=~- Drug-DNA Complex 
The concentration of the bound drug (c) can be related to the concentration of the 
unbound drug by the law of mass action: 
K=rlc(n-r) Equation 1 
Where K is the affmity constant and is the ratio of association and dissociation 
constants KJ + K2 
r is the concentration of bound drug per DNAp (concentration of DNA is 
expressed in terms of phosphate) 
c is the concentration of unbound drug and 
n is the number of binding sites for drug per DNAp 
Rearranging equation 1 to a linear form (equation 2) usmg the method of 
Scatchard [54] allows calculation of both K and n. 
ric =Kn -Kr Equation 2 
A plot of ric versus r should yield a straight line of gradient -K and intercept on 
the r axis, which is equal to Kn. 
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2.2.3 Fluorescence Studies 
Fluorescence spectroscopy, in much the same way as UV spectroscopy, can be 
used to characterise DNA-drug interactions [55]. It has previously been shown 
that the nature of interaction of drugs with DNA and the relative affinity of these 
drugs for DNA can be determined using fluorescence spectroscopy. 
Ethidium bromide, a known intercalator [34,56] shows a large enhancement of 
quantum yield of fluorescence on binding to DNA and therefore is considered to 
be an ideal fluorescent probe. Hence if a compound binds to the same site in the 
DNA helix as the ethidium bromide it will compete with ethidium bromide for 
that site. Providing that the fluorescence of the ethidium bromide in the absence 
of DNA is not effected by the drug under investigation it is possible to examine 
the effect of that drug on the fluorescence enhancement of ethidium bromide 
when bound to DNA [57]. 
2.2.4 Thermal Denaturation Studies 
The interaction of DNA binding drugs can also be studied by monitoring their 
effects on the physical properties of DNA. In particular viscometry [58,59] and 
thermal denaturation [58,59] of DNA-drug complexes can be used to provide 
further information about drugs that bind DNA. The latter technique was 
employed in this study to investigate the stabilisation of the DNA double helix to 
heat denaturation by the peptide conjugates. Thermal denaturation of DNA in the 
presence of drug leads to changes in its the physical properties. These changes 
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can be monitored where they are independent of the spectral properties of the drug 
[60]. 
Native DNA undergoes a transition to the denatured single stranded form when 
subjected to an increase in temperature. This transition results from the rupturing 
of the hydrogen bonds that hold the DNA strands together. Since the extinction 
coefficient of denatured DNA at 260nm is greater than that of native duplex DNA 
the rate of thermal denaturation can be followed spectrophotometric ally as the 
temperature of the sample is increased. The temperature corresponding to half the 
increase in the relative absorbance is designated the melting temperature, Tm. The 
T m is greatly influenced by the ionic strength of the buffer and the base 
composition of DNA [59], since, for example, a high GC content confers a higher 
thermal stability [59]. The presence of drugs that stabilise the DNA duplex 
through intercalation or other modes of binding (i.e. non-intercalative) will also 
lead to an increase in Tm of DNA [58,59], since more energy is required to 
separate the strands of the double helix. The increased stability imparted to the 
DNA helix by the drug can also be used as an indicator of its binding affmity. 
2.2.5 Electrophoretic Mobility Shift Assay (EMSA) 
DNA binding proteins play a major role in gene expreSSIOn through their 
involvement in transcription, replication and recombination. The study of DNA-
protein interactions has been markedly facilitated in recent years by ""gel 
retardation" or "gel mobility shift" assays [61,62]. This technique is based on the 
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observation that the electrophoretic mobility of a DNA fragment in gels is greatly 
retarded upon binding of a protein fragment [61]. These assays can therefore be 
employed to determine the selectivity, specificity and binding activity of DNA 
binding ligands. 
2.3 Structural Studies 
There are a number of techniques that can be used for determining the structure of 
peptides and proteins. NMR spectroscopy, Circular Dichroism (CD) and 
computerised molecular modelling techniques are amongst the most useful 
methodologies used in conformational analysis and DNA-drug interactions. 
2.3.1 Nuclear Magnetic Resonance 
The number of macromolecular structures that have been resolved using two-
dimensional (2D) NMR techniques has dramatically increased over the past few 
years. Homonuclear correlated spectroscopy (COSY) and Nuclear Overhauser 
Enhancement Spectroscopy (NOESY) are the two most commonly employed 2D-
techniques in the elucidation of the structure and function of biologically 
important molecules [63]. The spectra obtained from these experiments are 
presented in a two-dimensional manner (pseudo 3D) which allows much more 
information to be assembled and correlated than would be conceivable in a nonnal 
one-dimensional plot [64]. 
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2.3.1.1 COSY Spectroscopy 
COSY spectroscopy is often employed in disentangling complicated proton 
spectra as it allows the determination of how various protons in a molecule are 
coupled to each other i.e. it establishes proton-proton coupling. Since coupled 
protons are usually separated by two or three bonds, the connectivity and very 
often the chemical structure of a molecule can be derived from a COSY spectrum 
[63]. This technique is therefore extremely important in the structural analysis of 
complex organic and biochemical compounds, which are often characterised by 
intensive signal overlap where coupled nuclei cannot be identified on the basis of 
simple multiplet peaks [63]. The spectrum obtained from this experiment is set 
out along the x-axis and, in homonuclear COSY, repeated along the y-axis and 
repeated yet again in the contours of the diagonal peaks. Correlation between 
protons i.e. proton-proton coupling is indicated by the contour of an off-diagonal 
crosspeak. Spreading the data across an additional axis greatly enhances the ease 
with which interpretation is possible. 
2.3.1.2 NOESY Spectroscopy 
NOESY spectroscopy is by far the most important technique in the solution phase 
conformational analysis of large and complex molecules. The correlation signals 
i.e. crosspeaks generated from a NOESY experiment result from non-scalar 
interactions between nuclei which are in a close spatial relationship and are not 
necessarily coupled to each other. This technique provides, through interatomic 
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distance informatio~ details of molecular conformation. It thus enables the 
secondary and tertiary structure of pep tides and proteins to be determined [65]. 
2.3.2 Circular Dichroism Spectroscopy 
CD spectroscopy is a sensitive analytical tool used to obtain information 
regarding the secondary and tertiary structure of peptides and proteins. Basically 
CD is the differential absorption exhibited by an optically active molecule for left 
and right circularly polarised light [66]. This technique is particularly sensitive in 
establishing the conformation of small peptidic molecules, the structure of which 
may not be as apparent using alternative analytical tools such as NMR in which 
the complexity of the spectra can sometimes make complete structural elucidation 
difficult. It was anticipated that the peptides employed in this synthesis would 
either demonstrate a tendency to adopt a-helical conformations or appear as 
random coils i.e. unordered. 
2.3.3 Molecular Modelling 
Computer graphics, or molecular modelling, has become a very powerful tool in 
the field of drug design and development. This is because it allows theoretical 
studies of the interaction between a substrate (drug) and receptor (e.g. protein, 
DNA) of known structure to be modelled visually [67]. The studies obtained from 
this technique can identify and defme the possible key details of the molecular 
interaction and hence decide on optimal structural modifications likely to enhance 
either general binding affmity or recognition of specific binding sites. Molecular 
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modelling, however, is limited in that its results are focused only on the structural 
and electronic aspects of the actual molecular interaction and does not normally 
take into consideration factors such as drug absorption, transport and metabo lism 
[67]. 
The techniques described in this chapter were employed in both the synthesis and 
evaluation of the peptides. It was anticipated that the biophysical studies would 
determine the binding activity of the transcription factor inhibitors and that the 




3 SYNTHESIS - RESULTS AND DISCUSSION 
Synthesis of the potential AP-l transcription factor inhibitors involved three 
stages, fIrstly, synthesis of peptides representing the DNA binding domains of the 
fos and jun proteins, secondly, attachment of linker/spacer groups to intercalating 
chromophores (i.e. synthesis of intercalator-linkers) and fmally coupling the 
peptidic moieties to the intercalator-linker groups. This chapter describes and 
discusses the procedures involved in synthesising the intercalator-linked peptides 
and the results obtained. 
3.1 Peptides 
3.1.1 Target Sequence 
The tri-amino acid sequence i.e. Lys-Cys-Arg, which is highly conserved in the 
DNA binding domains of the AP-l protein was incorporated in the peptides 
employed in this synthesis. It was anticipated that short, truncated sequences of 
5-7 residues bearing this motif would have the potential to bind the DNA AP-l 
site in a redox sensitive manner. The Cys residue, essential for its thiol function, 
was expected to mimic that in the fos and jun proteins, behaving like a redox 
switch, permitting DNA binding of the drug (in tumour cells) under oxidative 
stress but preventing binding under oxic conditions. The Cys residue, therefore, 
was expected not only to determine the DNA binding of these agents. but also to 
allow them to be selective under reducing/hypoxic conditions. 
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The Arg and Lys residues, which are basic amino acids, were incorporated to 
maintain the cationic charge of the peptide, thus making it more electrostatically 
compatible with the phosphodiester backbone of DNA. As discussed earlier in 
section 1.3.4, these basic residues also enhance the reactive nature of the Cys 
residue, making it readily susceptible to oxidation and hence an attractive 
candidate for redox regulation [29]. 
3.1.2 Peptide synthesis 
Following initial semi-automated synthesis of two peptides, the remaining eight 
peptides of various amino acid sequences were custom synthesised by 
Calbiochem-Novabiochem Ltd. Six analogous peptides bearing the KCR motif 
and two further peptides with RCK and KSR motifs were obtained. These 
peptides are discussed later in section 3.4. The following section, however, 
describes the synthesis of the desired peptides using both solid and solution phase 
techniques. 
3.2 Solid Phase Peptide Synthesis 
A NovaSyn Gem Peptide synthesiser was employed to synthesise the two peptide 
sequences shown in figure 19. The method of SPPS adopted was continuous 
flow, in which the Fmoc strategy [41] was employed, where the a- amino group 
and the side-chain functionalities of the amino acid residues were protected with 






Figure 19 Peptides Sequences I and II Synthesised using SPPS 
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Peptides sequences I and II bear the reverse of the desired sequence i.e. RCK as 
opposed to KCR which is found in the DNA binding domains of the AP-l 
protein. These peptides were synthesised to provide suitable controls and to help 
establish the importance of the KCR motif in the DNA binding of both the AP-l 
protein and the peptide. The two peptides have different terminal groups, i.e. an 
acid and an amide group. The purpose of this was to determine whether the 
terminal group plays a role in the binding efficiency of the peptide to DNA. 
3.2.1 The Peptide Synthesiser 
The peptide synthesizer employed was semi-automated, in which the chemical 
processes for deprotection, washing and acylation were automated. but the 
preparation and addition of the activated sample and reaction monitoring had to be 
carried out manually. The flow scheme of a simple computer semi-automated 









Figure 20 Schematic Diagram of a Semi-automated Peptide Synthesizer 
3.2.2 Insoluble Supports and Solvents 
The solid supports FmocAla-NovaSyn TGA and NovaSyn PR500 were employed 
to synthesise the peptide acid and peptide amide respectively. The structures and 
loading potentials of these resins are shown in table 2. In each case the resins 
were solvated with dimethylformamide (DMF) for approximately 45min prior to 
use. This was necessary as the reactions involved in SPPS not only occur on the 
surface of the polymer but also inside the particles where reactants enter and lea\e 
by diffusion. Appropriate swelling of the support was therefore essential for the 
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maximum access and hence interaction of the reactants with the resin. Product 
formation was further enhanced by use ofDMF, a polar solvent, which increased 
the solubility of both the N-a protected amino acid residues and the reagents 
employed. DMF is known to decompose, liberating basic amino functionalities 
into solution, which are capable of cleaving the Fmoc group of the incoming 
amino acid residues and hence interfering with the growing peptide. For this 
reason the DMF used was distilled every 2-3 days. 























The coupling agent used in this instance was PyBOP, which is very similar to 
and therefore often compared with benzotriazole-l-yl-oxy-tris-
(dimethylamino )phosphonium hexafluorophosphate (BOP), figure 21, which is 
an excellent peptide coupling reagent. PyBOP is often used in place of BOP, as 
it is as efficient and in some cases has shown to cause less racemization. In 
addition, unlike BOP, it does not form the carcinogenic by-product hexamethyl 
phosphoramide [68]. 
Figure 21 'BOP' 
In this reaction (reaction scheme 1) diisopropylethylamine (DIEA) was 
employed to abstract a proton from the carboxyl group of the amino acid to 
generate a carboxylate ion. This anion then attacks PyBOP in a nucleophilic 
displacement reaction, where an amino-phosphorous ester and the auxiliary 
nucleophile, HOBt, are generated. 
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Reaction Scheme 1 
o 0 
II II 
RC-OH + DIEA ....:..... - .... RC-O- + DIEAH+ 
~ - N,N_-N-O~P4.~ (.~ n. + ~O\l 
RC-O + Q) [~--~"RC-Lo1pL ~3+ 








HOBt behaves like a second nucleophile, destroying the highly activated 
phosphorous ester and generating the benzotriazolyl ester of the amino acid 
residue. This is followed by nucleophilic attack of the carbonyl carbon by the 
amino group of the resin-supported peptide, which results in the formation of the 
desired product and the generation ofHOBt. 
3.2.3.1 Acylation Monitoring 
Each acylation step was monitored using the Kaiser test, which is a qualitative 
colorimetric assay [42]. This essentially involved removing a small aliquot of 
the resin (3-Smg) from the reaction vessel and treating it sequentially with a few 
Chapter Three 
drops of each of ninhydrin in ethanol, potassium cyanide in ethanol and fInally 
phenol in ethanol at 120°C for a few minutes. The presence of unreacted 
primary amino groups was indicated by a strong blue-purple colour, indicative 
of unsuccessful acylation, in which case a further batch of acylating mixture was 
introduced. A yellow-green colour however indicated that acylation had gone to 
completion and it was therefore possible to progress to the next stage of the 
synthesis. 
3.2.4 Deprotection 
The base labile Fmoc protecting group was removed from the N-terminal amino 
acid by proton abstraction using 20% piperidine in DMF. This reaction involves 
the generation of a carbamic acid, which loses carbon dioxide to afford the free 
amine, as shown in reaction scheme 2. 
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Reaction Scheme 2 
o 
H ~ ~ o~ 0 
CH2-OC-NHCHR -C-PEP------'~ 











R = Amino acid side-chain; PEP = Resin Bound Peptide 
3.2.4.1 Deprotection Monitoring 
The progress of each deprotection step was monitored usmg an UV 
spectrophotometer. A single absorbance peak identified the cleaved Fmoc group 
as the dibenzofulvene at approximately 310nm. The UV traces were also 
indicative of any peptide-chain aggregation, which was characterised by the 
broadening of the deprotection band. This occurred where there were difficulties 
of access for the base to the peptide amino terminus and therefore determined 
the likelihood of encountering difficulties with the subsequent coupling reaction. 
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When such broadening was observed, a longer acylation period was utilised for 
coupling the fo llowing amino acid. 
3.2.5 Final Deprotection and Cleavage 
Complete deprotection and cleavage of the peptide from the resin was achieved 
using TFA (92.5%) and a mixture of scavengers i.e. ethanedithiol (EDT; 2.5%), 
triisopropylsilane (TIS; 2.5%) and water (2.5%). Scavengers are reagents that 
trap reactive TFA-liberated carbonium ions and thereby prevent them from 
undergoing deleterious reactions with sensitive amino acids. The presence of 
scavengers was particularly important in the TFA deprotection of Cys(Trt) 
which in the absence of such reagents is reversible. The Trt protecting group is 
efficiently scavenged by TIS which prevents its reattachment to the Cys residue 
[69]. EDT, which also assists in the deprotection of Cys(Trt), and water were 
employed as they are known to accelerate the removal of the Mtr and Pmc 
protecting groups in TF A [37]. 
3.2.6 Pentamer Synthesis 
The synthesis of the two pentamers followed the protocol shown in figure 22. 
The NovaSyn TGA resin employed in this synthesis had been pre-loaded with 
FmocAla-OH, hence the first step shown in the protocol was only applicable to 
the NovaSyn PR500 resin. 
55 
Ch apfer Til ree 
In each case, the ammo acid residue was treated with base i.e. DIEA and 
activated with PyBOP in DMF a few minutes prior to its introduction to the 
reaction vessel. Acylation, on average took approximately 2hr, however longer 
coupling times were required for the attachment of the Cys and Arg residues. 
This was likely to be due to the steric hindrance created by the bulky protecting 
groups used to protect their side-chain functionalities i.e. the Trt and Pmc groups 
of Cys and Arg respectively. The time allocated for the removal of the Fmoc 
group using 200/0 piperidine in DMF was 20min. The two pentamers were left 
attached to their respective resins in order to facilitate later reactions involving 
the attachment of the intercalator-linkers (section 3.6) on the solid phase and 
also to enable the use of excess reagents. 
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Fmoe-Ala-Arg(Pmc )-Cys (Trt)-Lys (Boc Ala-RESIN 
Figure 22 Synthesis of Peptide Sequence I Using SPPS 
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3.3 Solution Phase Peptide Synthesis 
Although SPPS was the favoured method, solution phase synthesis of the peptide 
(bearing the KCR motif) shown in its protected fonn , in figure 23 , was also 
attempted. 
(Mtr)NH~ " N H 
~C--
I 
NH(Boc) S(Trt) NH 
I I I 
C
1 
H3 (CH2)4 CH2 (CH2)3 CH ~ I I I I -
FmocNH- CH- CO-NH-CH-CO- NH-CH-CO -NH -CH-CO-N H-CH-C0 2- CH3 
Ala Lys Cys Arg Ala 
Figure 23 'Protected' Pentapeptide 
This method of peptide synthesis, however proved to be both di fficult and time 
consuming, this was due to the problems encountered with both the stability and 
purification of the peptidic intennediates. This instabili ty was found to be more 
prominent where an ester group had been used to protect the carboxyl function of 
the amino acid residue . This was especially true of the dipeptide-ester, ' Arg(Mtr)-
Ala .OCH3', which was synthesised using a standard coupling procedure, in whi ch 
EDC and HOBt were employed, followed by the removal of the Fmoc gro up 
using 20% piperidine in dichloromethane. 
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Reaction Scheme 3 
I. Acylation 








H3 (CH2h CH3 
EDC I I 
FrmcNHCH-COOH + NH2-CH-COOCH3 ---.. FrmcNHCH-CO-NHCH-COOCH3 
Mechanism 
q> 4~ 
--•• RC~C-NHRI + HOBt 
o 
" + RHNCNIOC 
o 
" RCNHIi + HOBt 
(EOU) 
R= FmocNHCH(CH2)3NHCNHNH(Mtr); RI = CH2CH3; R2 = (CH2)3NMe2; 







II. Selective Deprotection 
It became apparent from Nuclear Magnetic Resonance (NMR) and Infrared (IR) 
spectroscopy that the deprotected dipeptide-ester had not been iso lated, this was 
indicated by the absence of the methoxy group of the alanine (Ala) residue. The 
absence of this group suggested that the deprotected dipeptide-ester was 
undergoing cyclisation to form a 2,5-diketopiperazine (DKP) ring [37], as shown 
in reaction scheme 4. 
Reaction Scheme 4 
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In an attempt to avoid DKP fonnation, the ester function of the Ala residue was 
transfonned to its corresponding amide using (sg 0.88) N~OHlCH30H. 
Concomitant deprotection of the Fmoc group was also anticipated. 
Reaction Scheme 5 




(SH2)3 ~H3 (SH2)3 ~H3 
FmocNH-CH -CO-NH -CH -COOCH3 -----.~ NHrCH -CO-NH -CH -CONH2 
Isolation of this product, however was not successful, and it was likely that 
transamidation had occurred. Due to both the lack of time and the problems 
encountered with this method, solution phase peptide synthesis was no longer 
pursued. 
3.4 Peptide Sequences 
As mentioned earlier in section 3.1.2, six analogous peptides bearing the KCR 
motif and a further one with the reverse sequence i.e. RCK, with amide and acid 
termini respectively were obtained from Calbiochem-Novabiochem. These are 
shown in figure 24. A control peptide mimicking the binding domains of the 
oncogenic homologues of the fos and jun proteins, i.e. v-fos and v-jun respectively 
was also acquired. These oncogene products contain the KSR motif, the serine 
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residue of which is not subject to redox regulation and thus permits D A binding 

















Figure 24 Custom Synthesised Peptides 
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All eight peptides were synthesised using Fmoc chemistry and were supplied fully 
protected and bound to resin. The a-amino termini and the side chain 
functionalities were masked with the base labile Fmoc group and acid labile 
protecting groups respectively. 
3.4.1 Isolation of the Free Peptide 
In each case a small amount of the peptide was isolated and analysed in its free 
form. The purpose of which was to ensure that the desired peptide had been 
synthesised and that complete deprotection was being achieved. Isolation of the 
free peptide was achieved by fIrstly removing the N-terminal Fmoc group using 
20% piperidine in DMF. This was then followed by treating the resin with the 
same cocktail of scavengers discussed earlier in 3.2.5, that is, EDT (2.5%), TIS 
(2.5%) and water (2.5%) in TFA to simultaneously remove the acid labile 
protecting groups and to cleave the peptide from its solid support. 
3.4.2 Purification of the Peptides 
Purification of peptide one was attempted using High Performance Liquid 
Chromatography (HPLC). A C8 reverse phase column and eluent mixture 
of water with an increasing gradient of methanol with 1% trifluoroacetic 
acid was employed. Figure 25 shows the HPLC chromatogram of peptide 
one prior to purification. Isolation of the pure peptide however was 
problematicaL as the retention time of the desired peak seemed to be 
variable and analysis of the [mal product suggested that the purifIed peptide 
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was undergoing degradation on standing in the eluent medium. This was 
indicated by the increase in the number of impurities, i.e. peaks observed in 
the chromatogram of the [mal product after purification (figure 26). Due to 
the problems encountered with the HPLC of peptide one, this method of 
purification was no longer employed. However in order to eliminate the 
need for purification and hence minimise the number of impurities the resin-
bound peptide was washed thoroughly, at the end of each stage with a range 
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Figure 25 HPLC Chromatogram of Peptide One Prior to Purification 
Using a C8 Reverse Phase Column and an of Eluent Water with an 
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Figure 26 HPLC Chromatogram of Peptide One Post Purification Using a 
C8 Reverse Phase Column and an of Eluent Water with an Increasing 
Gradient of Methanol 
66 
Chapter Three 
The crude peptides were analysed using HPLC and Matrix Assisted Laser 
Desorption Ionisation Mass Spectrometry (MALDI-MS) to ensure that the 
desired peptides had been isolated. Mass spectral analysis of peptides 1, 5 
and 6, however, suggested that the deprotection process was incomplete. 
This was indicated by the presence of peaks corresponding to the molecular 
weights of both free and partially protected peptide (figure 27). This 
suggested that the scavengers employed were not sufficiently suppressing 
the electrophilic species generated during the cleavage process, which react 
with the functionalities of sensitive amino acid residues. In order to ensure 
complete deprotection of the peptides, the amount of each scavenger and the 
time allowed for the process was increased from 2.5% and 4 hours to 5% 
and 5 hours respectively. The results hereafter indicated that complete 
























Figure 27 MALDI Mass Spectrum of Peptide One after Deprotection and 
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Figure 28 MALDI Mass Spectrum of Peptide One after Deprotection and 






The role of the intercalator is essentially to deliver the peptide hybrid to 
nuclear DNA. It was envisaged that the non-specific binding of the 
intercalating chromophore would also stabilise the weaker specific binding 
of the peptide, the whole providing both high DNA affinity coupled with 
sequence selectivity. Unfortunately, however, as the chromophore stacks 
between the adjacent base pairs of DNA it causes local unwinding of the 
DNA [32]. This distortion of the double helix at the site of intercalation 
may therefore disrupt DNA binding of the peptide moiety of the conjugate. 
For this reason a 'spacer' or 'linker' group was employed to distance the 
peptide and intercalator binding sites. 
3.5.2 Linker 
In addition to providing a spacer to allow minimal disruption of the AP-l 
binding domain by intercalation of the chromophore, the linker group was 
incorporated in order to ascertain a spatial arrangement which allowed the 
unrestricted or unhindered movement of the peptide with respect to the 
intercalated chromophore. It was anticipated that this would effectively 
allow the peptide to search for the DNA AP-l site. A number of linker 
groups of various lengths were investigated in order to detennine the 
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ideal/optimal length necessary to provide the maximum spatial orientation 
required to ensure the binding of the peptide with the DNA AP-l site. 
3.5.3 Intercalator-Linker Synthesis 
The next section describes the procedures involved in attaching various 
linker moieties to desired intercalators. The intercalator primarily employed 
in this synthesis was anthraquinone, although the acridine and 
anthrapyrazole chromophores were also explored. The anthrapyrazoles 
however were investigated by co-workers [70,71]. The termini of the 
linkers employed were either carboxyl or chloro groups, in order that 
attachment of the desired peptides might be achieved using standard 
acylation and alkylation conditions. 
3.5.3.1 Synthesis of 1-[N-{2-Succinamidylethyl}amino]anthraquinone (A) 
Product 
Preparation of 1_[N_{2_succinamidylethyl}amino]anthraquinone entailed a two 
step process. The fIrst reaction involved a nucleophilic displacement reaction in 
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which l-chloroanthraquinone was reacted with excess ethylenediamine to yield 1-
[N-{2-aminoethyl} amino] anthraquinone. This was then acylated with succinic 
anhydride in DMF to afford the desired product in a 72% yield. The products in 
both cases were purified using column chromatography. 















0 0 NH(CH2hNHC(CH2)2COH 





3.5.3.2 Synthesis of 1-[N-{2-(2-Succinamylethyl)succinamidyl}ethyl]amino-
anthraquinone (B) 
Product 
Intercalator-linker B is essentially an extension of A and very similar to C (section 
3.5.3.3) except that unlike the latter it does not posses any free amino groups 
which are required for the formation of non-specific salt bridges. The linker 
length in B was increased from 8 atoms in A to 16 by repeating the addition of the 
linker twice. The carboxyl function of A was activated with PyBOP, in the 
presence of DIEA, and then amidated with excess ethylenediamine, in an attempt 
to prevent dimerisation, to afford 1_[2_{N_(2_succinamylethyl)succinamidyl}-
ethylamino ] anthraquinone. This was further reacted with succinic anhydride to 
yield intercalator-linker B in a 25% yield. In both cases the products were 
purified using column chromatography. 
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3.S.3.3 Synthesis of I-N-[2-{N-[(S,S)-S-Amino-S-carboxypentyl]succinamyl}-








x = Peptide 
Intercalators C and D are also extended forms of intercalator-linker A. The linker 
length was increased from 8 to 15 atoms using a single Lys and from 8 to 22 
atoms using two Lys residues (connected through the E-amino groups) for 
compounds C and D respectively. This was achieved by linking the Lys 
residue(s) directly onto the peptide after which the intercalator moiety i.e. A was 
attached. It was anticipated that the pendant primary amino groupe s) present in 
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the linker would increase the range of non-specific contacts with DNA and hence 
would further enhance the affmity of these conjugates for DNA. 
In order to achieve this extension of the peptides by lysyl residues, orthogonal 
amino protecting groups were required. The E-ammo group of BocLys-OH was 
protected using 9-fluorenylmethyloxycarbonyl-N-hydroxysuccinimide (Fmoc-
OSu) to afford BocLys(Fmoc)OH. This was then used to acylate the termmal 
ammo group of a resin bound peptide using PyBOP. The Fmoc group was then 
selectively removed and the E-ammo group was subsequently amidated with A to 
afford conjugate C. In the case of D, a second lysine residue was incorporated 
before fmally attaching A. The synthetic route employed to synthesise conjugate 
C is shown in reaction scheme 8. 
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Reaction Scheme 8 
NH(Boc) 
I 
FmocNH(CH?) tCH-C- OH + ~H/ -PEPTIDE-RESIN - ~ II -
o 1 Amidation 
NH(Boc) 
I 






NH, (CH2).+CH-C- N H -PEPTIDE-RESIN - II 
o 
1 Amidation with A 
N H(Boc) 





3.5.3.4 Synthesis of 1-[2-{N-(2-Chloroethyl)-N-methylamino}ethylamino]-
anthraquinone (E) 
Product 
Synthesis of the 1-[2-{N-(2-chloroethyl)-N -methy lamino } ethy lamino ]-
anthraquinone (E) involved three main steps [72]. The first of which entailed the 
preparation of the amino-alcohol linker group, i.e. 2-{N-(2-hydroxyethyl)-N-
methylamino }ethylamine. The synthesis of this side-chain was attempted using 
two different methods which have been described below. 
Reaction I Synthesis of 2_[N_{2_Hydroxyethyl}-N-methylamino]ethylamine 
Method A 
Method A was initially chosen for its simplicity as it involved a one step 
procedure in which neither of the amino components used required protection (see 
reaction scheme 9). This method essentially involved refluxing bromoethylamine 
hydro bromide in excess 2-(N-methylamino ) ethano I for Shr. Although purification 
of the product isolated was attempted using kugurohr distillation, Thin Layer 
Chromatography (TLC) of the resultant yellow oil indicated that the desired 
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ammo ethanol side-chain was present only in a small proportion amongst a 
number of impurities including 2-(N-methylamino ) ethanol. Due to the difficulties 
m isolating pure 2-[N-{2-hydroxyethyl }-N-methylamino ]ethylamine an 
alternative strategy was adopted in which amino protection was employed. 
Reaction Scheme 9 
Method B 
Synthesis of the amino-ethanol side chain using this procedure involved three 
stages [72]. In the first step the primary amino group of N-methylethylene-
diamine was selectively protected with benzophenone, the carbonyl carbon of 
which undergoes nucleophilic attack with primary amines, followed by 
dehydration to form the corresponding imine. The reactants were refluxed in 
xylene, a high boiling solvent, using a Dean-Stark apparatus to remove the water 
generated during the course of the reaction. The reaction was performed in the 
presence of boron trifluoride etherate, a Lewis acid, to enhance the electrophilic 
nature ofbenzophenone, making it more readily susceptible to nucleophilic attack. 
The product was subsequently treated with ethylene oxide, which underwent base 
catalysed ring opening to give the desired product. Removal of the benzophenone 
protecting group was achieved by protonation of the imine, making it susceptible 
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to hydrolysis, using 5M hydrochloric acid. The desired product was isolated 
using kugurohr distillation. 
Reaction Scheme 10 
Comparisons of the two products using TLC and NMR (figure 29) indicated that 
the amino-ethanol side-chain synthesised using method B was more pure than that 
iso lated from method A. The greater purity of the product iso lated from method 
B was due to the extremely volatile nature of ethylene oxide, the removal of 
which was easily achieved compared to that of2-(N-methylamino)ethanol used in 
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Figure 29 NMR Spectra of 2-{N-(2-Hydroxyethyl)-N-methylamino}ethyl-
amine Isolated from Method A 0) and Method B (ii) 
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Reaction II Synthesis of 1-[2-{N-(2-Hydroxyethyl)-N-methylamino}ethyl-
amino]anthraquinone 
Attachment of the amino ethanol side-chain to the intercalating chromophore was 
achieved by refluxing 1-chloroanthraquinone in excess 2-[N-{hydroxyethyl}-N-
methylamino ]ethylamine under nitrogen for 18hrs. The product was isolated as a 
red solid with two major impurities, which were unreacted l-chloroanthraquinone 
and the amino-ethanol side-chain. A 12% yield of the desired product was 
isolated after purification, using column chromatography. The low yield obtained 
for this reaction was attributed to the poor electrophilic nature of 1-
chloroanthraquinone, which was used in favour of the more reactive 1-
fluoroanthraquinone for its commercial availability. 












The hydrochloride salt of 1-[2-{N-(2-hydroxyethy 1)-N -methyl amino } ethylamino]-
anthraquinone was prepared in order to prevent the amino groups from interfering 
in the subsequent chlorination reaction. This was necessary as it had previously 
been shown by HPLC [72] that chlorination of 1-[2-{N-(2-hydroxyethyl)-N-
methylamino} ethyl-amine ] anthraquinone without prior hydrochlorination resulted 
in multiple products. Preparation of the salt was achieved using ethereal 
hydrogen chloride. Addition of the latter solution to 1-[2-{N-(2-hydroxyethyl)-N-
methyl amino }ethylamine ] anthraquinone in dichloromethane resulted in the 
formation of a precipitate and a colour change from red to orange indicating 
protonation of the secondary amine. 




Reaction IV Synthesis of 1-[2-{N-(2-Chloroethyl)-N-methylamino}ethyl-
amino]anthraquinone 
Thionyl chloride was initially used to transform 1-[2-{N-(2-hydroxyethyl)-N-
methylamino }ethylamine ] anthraquinone to its corresponding chloroethvl 
(mustard) derivative. However the product was isolated in low yield (9%) and 
hence an alternative method was employed in which the hydroxy derivative was 
treated with triphenylphosphine and carbon tetrachloride in dichloromethane [73]. 
The product was purified by column chromatography to remove the residual 
triphenylphosphine and triphenylphosphine oxide, and was isolated in a 68% 
yield. The greater yield obtained with this method was attributed to the milder 
chlorination conditions provided by triphenylphosphine and carbon tetrachloride 
reagents compared to thionyl chloride, the use of which resulted in the formation 
of a number of by-products. 









3.5.3.5 Synthesis of 2-[2-{N-(2Chloroethyl)-N-methylamino}ethylamino]_ 
anthra[I,9-c,d,]pyrazol-6(2H)one (F) [70,71] 
Product 
o 
An anthrapyrazole intercalator was employed as an alternative to anthraquinone to 
determine the effect of the chromophore structure on the DNA binding of the 
peptide. Synthesis of this intercalator-linker involved four reactions, the first of 
which entailed refiuxing aziridineethanol in hydrazine monohydrate, the former of 
which underwent nucleophilic attack to afford substituted hydrazine (i). This was 
treated with l-chloroanthraquinone, in the presence of triethylamine, in 
acetonitrile to yield an anthrapyrazole (ii), which was subsequently methylated 
using formic acid and formaldehyde. The product (iii) was chlorinated using 
carbon tetrachloride and tiphenylphosphine, as described in section 3.5.3.4, to 
afford the desired product (iv) in a 57% yield after recrystallisation from hot 
methanol. 
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3.5.3.6 Synthesis of 7-[2-{Succinamidoethyl}amino]-2-[2-{N-(hydroxyethyl)_ 




Intercalator-linker G was employed to assess the effect of a second side-chain on 
the DNA binding of the peptide moiety. Synthesis of this intercalator-linker 
involved five reactions, the first three of which were essentially the same as those 
described in the synthesis of intercalator-linker F, except that 1 5-, 
dichloroanthraquinone was used in place of l-chloroanthraquinone. Attachment 
of the second side-chain involved sequential amination and amidation with 
ethylenediamine and succinic anhydride respectively, as in the synthesis of 
intercalator-linker A (section 3.5.3.1). The product was isolated in an 11.5% 
overall yield. 
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3.5.3.7 Synthesis of 9-[S-{Carboxymethyl} mercapto]acridine (H) 
Product 
The acridine chromophore, a known intercalator of DNA, was also investigated as 
an alternative to the anthraquinone intercalataor [32,53]. 9-Chloroacridine was 
reacted with thioglycolic acid in methanol in the presence of DIEA. Thioglycolic 
acid was used as opposed to an amino or amino acid moiety due to the stronger 
nucleophilic nature of the sulphur atom and its ability to avoid zwitterion 
formation. The product was isolated as yellow solid, in a 70% yield after column 
chromatography. 
Reaction Scheme 16 




3.5.4 Attempted Synthesis 
In addition to those described earlier a number of alternative intercalator-linkers 
were also investigated, the isolation of these however was unsuccessful. The next 
section briefly describes the attempted synthesis of these compounds. 
2.5.4.1 Synthesis of 1-[N-{3-Carhoxypropyl}amino]anthraquinone 
Synthesis of 1-[N-{3-carboxypropyl}amino]anthraquinone involved a 
nucleophilic displacement reaction, in which the chloro group of 1-
chloroanthraquinone was to have been displaced by the amino group of y-
aminobutyric acid (GABA). Unfortunately, although this reaction is facile from a 
mechanistic point of view, a number of problems were encountered in practice. 
An initial attempt to synthesise 1-[N-{3-carboxypropyl}amino]anthraquinone in 
methanol with a few drops of acetic acid was unsuccessful, this was possibly due 
to the complete protonation of the amino group of GABA. Replacing acetic acid 
with triethylamine. in order to prevent zwitterion formation, also gave no product. 
Finally use of NaOH (lM) and the Lewis acid ZnCh in methanol provided the 
desired product in a 50 % crude yield. Use of 2-methoxyethanol allowed the 
temperature to be raised from 65 to 125°C. Although this enhanced the reaction 
rate, it had no effect on the reaction yield. 
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Reaction Scheme 17 
o o 
Purification of 1-[N-{3-carboxypropyl}amino ] anthraquinone was extremely 
difficult, as the product was only sparingly soluble in all assessed polar protic, 
polar approtic and non-polar solvents. The problems encountered with the 
solubility were attributed to the large difference in polarity of the non-polar 
anthraquinone chromophore and polar GABA side-chain. A number of attempts 
were made in order to purify the product. Techniques such as recrystallisation, 
column chromatography, dry flash chromatography and preparative thin layer 
chromatography were employed, however these methods of purification were 
unsuccessful. 
3.5.4.2 Synthesis of 1-[S-{Carboxymethyl}mercapto]anthraquinone 
l-[S-{Carboxymethyl)}mercapto ] anthraquinone was synthesised in the same 
manner as 1-[N-{3-carboxypropyl}amino ] anthraquinone. Purification of this 
yellow product was unsuccessful as similar problems were encountered with the 




Reaction Scheme 18 
o 
3.5.4.3 Synthesis of 1-[N-Methyl-N-carboxmethyl] anthraquinone 
The synthesis of l-[N-methyl-N-carboxmethyl]anthraquinone (reaction scheme 
19) was attempted to determine the effect of a tertiary amino group on the 
solubility of the anthraquinone-amino acid derivative. Sarcosine and 1-
chloroanthraquinone were refluxed in dimethylsulfoxide (DMSO) under nitrogen 
and a red product was isolated. This was purified using column chromatography 
from which two fractions were collected and analysed by IH-NMR. 





The NMR spectra indicated the presence of NCH3 and ArCH3 groupings but the 
resonance attributable to the expected NCH2C02H was not observed. This finding 
might be explained if the desired product had been formed, but had subsequently 
undergone rearrangement and decarboxylation as shown below. 











3.5.4.4 Synthesis of 9-[N-{2-Hydroxyethyl}amino]acridine 
Synthesis of 9-[N-{2-hydroxyethyl}amino]acridine was achieved bY 
reacting 9-chloroacridine with excess ethanolamine at room temperature. 
The product, after purification was then treated with p-toluenesulphonyl 
chloride in dry pyridine to afford its corresponding tosyl ester. Purification 
of this ester was attempted several times using column chromatography. 







NMR of the final product however suggested that the tosyl ester had 
decomposed, regenerating the amino alcohol. Due to the problems 
encountered with the alkylation of the peptides with intercalator-linkers E 
and F, which became apparent in parallel studies, the synthesis of alkylating 
moieties was no longer pursued. 
3.5.4.5 Synthesis of 9_[2_{Succinamylethyl}amino]acridine 
Synthesis of 9-[2-{ succinamy lethy I } amino] acridine was attempted usmg the 
method employed to synthesise compound A. 
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Isolation of the desired product was not achieved as ami nation of 9-chloroacridine 
resulted in dimer formation despite the use of excess diamine and dilute solutions 
(figure 30). This reaction was therefore no longer pursued. 
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Figure 30 Acridine Dimer 
The intercalator-linkers that were successfully synthesised were attached to the 
peptides described in section 3.4, figure 24. The next section describes the 
procedures involved in the preparation of the final intercalator linked peptides. 
3.6 Peptide Conjugates 
This section describes the methods employed in synthesising the peptide 
conjugates. The intercalator-linkers used and the conjugates synthesised have been 
shown in table 3. 
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../ Attempted Synthesis: Peptides l:ARCKA 2:AKCRA 3:AKSRA 







3.6.1 Conjugate Synthesis 
The N-terminal Fmoc group of each peptide was removed selectively with 20% 
piperidine in DMF. The free amino terminal of the peptide was then amidated or 
alkylated with the appropriate intercalator-linker whilst still attached to the solid 
support. Use of resin-supported peptide facilitated the use of excess 
alkylating/acylating components. Following extensive washing of the resin. 
isolation of the conjugates was achieved by treating the resin with a cocktail of 
scavengers in TFA as described in section 3.2.5. The protocols adopted for the 
carboxyl terminal intercalator-linker conjugates are discussed in section 3.6.2 and 
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I - I 
PEPTIDE(p)-RESIN PEPTIDE(P)-RESIN 
De protection and Cleavage 
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II 





I =Intercalator; R = Linker; PEPTIDE(P) = Protected Peptide; X = COOH or 
CONH2 terminus 
Figure 31 Protocol Adopted/or Conjugate Synthesis 
3.6.1.1 Synthesis of the A-D, G and H Conjugates 
Intercalator-linkers bearing a carboxyl terminus were amidated with the free amino 
terminal of the appropriate peptide for 3 hours using PyBOP and OlEA in OMF. 
102 
Chapter Three 




1) Ami dati on II 
NH2-PEPTIDE(P) ~ I-RC- NH - PEPTIDE-X I 2) DeJrotection . 
RESIN andOeawge 
I = Intercalator; R = Linker; PEPTIDE(P) = Protected Peptide ; X = COO H or 
The conjugate bound resin was washed sequentially with OMF, ethanol and ether to 
remove the excess of reagents and any impuriti es present, after whi ch the product 
was cleaved from resin . Analysis of the conjugates using MALOI-MS suggested 
that all the desired products except 4H had been isolated, fi gure 32 shows a typi ca l 
spectrum. The peak at 907 daltons corresponds to the desired peptide conj ugate 
(I A), the peak at 365 is a component of the MALOJ matri x. The spectrum of 4H 
indicated the presence of two components with molecul ar weights of 705 and 1409, 
neither of which corresponded to the free peptide or the desired product. The 
identity of the two products was not resol ved. Whil st the hi gher molec ul ar we igh 
impurities might suggest the presence of the partially protected peptide, there is no 
obvious explanation as to why the conditions utili sed should fai l in ac hie\·ing 
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3.6.1.2 E and F Conjugates 
The E and F conjugates were synthesised by alkylating the resin bound peptides 
with the appropriate intercalator-mustard. Peptides 1 to 4 and 1 to 2 were 
alkylated with intercalators Band C respectively in DMF. in the presence of 
DIEA for 3 hours. 
Reaction Scheme 23 
1) Acylation 
I-RCH2-Cl + NH2-PEPTIDE(P) .• I-RCH,- NH-PEPTIDE-X I 2) DeprotectlOn -
RES IN and Cleavage 
I = Intercalator; R = Linker; PEPTIDE(P) = Protected Peptide ; X = COOH or 
Analysis of these conjugates by MALDI-MS, however indicated that a pure form of 
the desired products had not been isolated. The spectra suggested that the 
alkylation of the peptide in each case was incomplete. This was indicated by the 
presence of a major and minor peak, which correlated to the free peptide and it s 



























Preparation of 4E was attempted several times using various reaction conditions. It 
was anticipated that repeated alkylation of the peptide with E would ensure that a 
100% reaction would be achieved. A small aliquot of peptide 4 (resin bound) was 
alkylated twice and a further aliquot was alkylated four times with the E 
intercalator-linker, after which the products were cleaved from resin. Analysis of 
4E in both cases using MALDI-MS showed that there was no marked improvement 
in the alkylation of peptide 4. An alternative base to DIE A, i.e. N. N-
dimethylaminopyridine (DMAP) was also employed in the anticipation that this 
would enhance the reaction yield. However the MALDI mass spectrum of the 
product isolated indicated that no improvement in the reaction had occurred. In a 
fmal attempt to alkylate the peptide, the reactions were conducted at 30°C and at 
45°C in the presence of DIEA. Although the reactions were left for up to 18 hours 
complete alkylation was not achieved. The poor alkylation of the peptides with 
both E and F suggested that these compounds were either undergoing degradation 
or that a portion of the resin-bound peptide had aggregated in such a fashion that it 
was no longer nucleophilic. 
3.6.1.2.1 Reactivity Studies 
Stability studies were conducted in an attempt to establish whether the intercalator-
linked mustards were undergoing degradation. The stability of E was determined in 
both DMF and methanol, both in the presence and absence of DIEA. The 
experiments were conducted at room temperature and at 45°C, and were monitored 
using TLC at regular time periods for 18hours. Degradation of E was anticipated to 
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be more pronounced in methanol, in the presence of base, as it was expected it to 
undergo nucleophilic attack by the solvent to afford its methoxy derivative as 
shown in reaction scheme 25. 
Reaction Scheme 24 
1= 
o 
The results obtained from these experiments indicated that E was relatively stable, 
although its methoxy derivative was observed in methanol when heated at 45°C in 
the presence ofDIEA. This however was only present in a minute quantity after 18 
hours. These results therefore indicate that the earlier lack of success in alkylation 
of the peptide was not due to the instability of the intercalator-linkers but rather to 
their poor reactivity. 
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3.6.1.2.2 Model Alkylation Studies 
The reactivity of E using benzylamine as a model was investigated in the 
anticipation that this would help establish the conditions necessary for the complete 
and successful alkylation of the peptides. Benzylamine was reacted with B under 
several conditions; these along with the results obtained are summarised in table .t. 
All reactions were monitored at regular time periods using TLC. 
Reaction Scheme 25 
o 
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Table 4 Reactivity Studies of Intercalator-Iinker E using Benzylamine 
Molar Equivalents of Reagents 
Method Inercalator- Benzylamine Base Solvent 
Linker E 
A 4 1 DIEA DMF 
B 4 1 DIEA DMF 
C 4 1 DMF 




25 No significant reaction after 
70 hours 




Complete reaction after 100 
hours 
Complete reaction after 5 
minutes 
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The results in general indicate that the alkylation of benzylamine with E is very 
much dependent on three factors, i.e. concentration, time and temperature. If the 
reaction is allowed to proceed at 37°C for a significant length of time then 
complete alkylation may be achieved, although if heated vigorously in excess 
amine the desired product will form almost instantaneously. Unfortunately. these 
extreme conditions cannot be employed in the synthesis of the desired conjugates, 
as the peptides are likely to undergo racemization and degradation. For this 
reason the synthesis of the E and F conjugates was no longer pursued. 
3.7 An Alpha Helical Constraint 
In addition to preparing unrestrained peptides in this project, the synthesis of a 
helical constrained peptide was also attempted. The method adopted was that 
described by Phelan and co-workers [50] in which an amide tether is formed 
between the i and i+ 7 residues of a peptide. In this case 1,4-diaminobutane was 
employed to bridge the glutamic acid residues at positions i and i+ 7 in a peptide, 
(i.e. peptide 9), bearing the KCR motif, figure 34. This section briefly describes the 




I r CH~l~ 
0yNH ""yO 
NH2-Glu-Ala-Lys-Cys-Arg-Lys-Arg-Glu-N H 
Figure 34 Peptide Nine Constrained using an Alkanediamine Chain 
It was expected that this conformational constraint would preferentially lock the 
peptide in an a-helical structure which is reminiscent of the basic domains of the 
AP-l protein when bound to DNA. It was anticipated that this amide bridge or 
constraint would prevent random coiling of the peptide and hence poss ibly 
increase the affmity of the peptide for the DNA AP-l site. This is highl y 
plausible since it has been previously reported that upon recognition of the DNA 
AP-l consensus sequence the basic regions of the fos and jun proteins become 
completely helical, thus allowing tight binding interactions [2 1]. The potentia l 
increase in affmity of the peptide for DNA would be expected as a result of a 
favourable change in the entropy of the binding to DNA. It was expected that 
there would be a relatively small loss of entropy upon binding of the constrained 
peptide to the DNA AP-l site as it would already be in its binding conformat ion. 
This is unlike the binding of the unrestrained peptides which. due to a loss of 
conformational flexibility, results in a considerable loss of ent ropy. It \\'as 
therefore anticipated that DNA binding of the constrained peptide. i. e . pept ide 9 
will occur more readily compared to that of the unrestrained peptides. 
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3.7.1 Peptide 9 
Peptide 9 was synthesised by Calbiochem-Novabiochem Ltd using SPPS and was 
supplied fully protected and bound to resin. The amino terminus was protected 
with the Fmoc group and all of the side chain functionalities, except those of the 
Glu residues were masked with various acid labile protecting groups. The 
carboxyl functions of the glutamic acid (Glu) residues at positions i and i + 7 were 
protected with ODmab and the hyper-acid labile group Opfp respectively. ODmab 
can be removed selectively using 2% hydrazine in DMF and Opfp is deprotected 
by 1 % TF A in dichloromethane. 
3.7.2 Amide Bridge 
l,4-Diaminobutane, which affords a 4-methylene bridge. had been previously 
shown to provide an optimal length for inducing and sustaining a-helicity in short 
peptides, thus preventing randomisation of the secondary structure [50]. 
Monoprotection of this diamine prior to its attachment to the peptide was 
necessary to prevent any undesirable reactions. It was prerequisite that the 
masking group used to monoprotect l,4-diaminobutane could be removed 
selectively and was stable to the conditions required to deprotect the two glutamic 
acid residues. 
Phthalic anhydride, which can be removed using 240/0 hydrazine in methanol [74] 
was employed to monoprotect the l,4-diaminobutane. The desired product \\as 
synthesised by refluxing this diamine with phthalic anhydride in chloroform for ~ 
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hours [74]. A white precipitate was isolated and purified USIng column 
chromatography to give the product in a 200/0 yield. 
Reaction Scheme 26 
o 
3.7.2.1 An Alternative Linker 
o 
N(CH2hNH2 + H20 
o 
The amino acid ornithine, which also provides a 4-methylene bridge, was 
employed as an alternative to 1,4-diaminobutane. This residue was obtained from 
Calbiochem-Novabiochem Ltd in the protected form of Fmoc-Om(Boc )OH. In 
order to attach this residue to peptide 9, it was first necessary to remove one of its 
two protecting groups and also to mask its carboxyl terminus. The latter was 
protected with a methyl ester function under acidic conditions, which therefore 
resulted in the removal of the Boc protecting group. Fmoc-Om(Boc )OH was 
dissolved in methanol and saturated with dry hydrogen chloride gas, which 
resulted in the simultaneous protection and deprotection of the carboxyl and amino 
functions respectively. The product was isolated as an off-\vhite solid. \\hich was 
purified using column chromatography. 
11 ~ 
Reaction Scheme 27 
(Boc)NH OH ~NH 






NMR analysis of the product however suggested that despite the presence of 
excess acid, it had undergone cyclisation as shown in reaction scheme 28. This 
unexpected lactam formation, coupled with the difficulties in completing the -t-
methylene bridge (discussed later in 3.7.3) led to the discontinuation of this 
synthesis. 








3.7.3 Synthesis of a Constrained Peptide 
The general scheme adopted for constraining peptide 9 using 1, 4-diamino butane is 
summarised in figure 35. Prior to each reaction involving acylation, the resin was 
solvated with DMF and at the end of each reaction the resin was washed 
thoroughly with DMF, ethanol and ether. 
116 
Chapter Three 
FmocN H lu (ODmab)-A la-Lys(X)-Cys(Y)-Arg(Z)-Lys(X)-Arg(Z ) III (Opfp)-RESIN 
l-Fmoc 
N H2-Glu (0 Dmab )-Ala-Lys(X)-Cys(Y)-A rg(Z)-Lys(X)-Arg(Z) lu (Opfp )-RESI N 
lA 
A-N H lu (ODmab)-A la-Lys(X)-Cys(Y)-A rg(Z)-Lys(X)-Arg(Z) III (Opfp)-RESIN 
0yOH l-oDmab 
A-N H-Glu -Ala-Lys(X)-Cys(Y)-Arg(Z)-Lys(X)-Arg(Z) III (Opfp)-RESIN 
0yNH(CH 2)"N -P 
A-N H lu -A la-Lys(X)-Cys(Y)-Arg(Z)-Lys(X)-A rg(Z) III (Opfp)-RESIN 
-Opfp 
0yNH(CH2)"N-P HOyO 
A-NH lu -Ala-Lys(X)-Cys(Y)-Arg(Z)-Lys(X)-Arg(Z) III -RESIN 
-p 
0yNH(CH2)"NH2 HOyO 
A-N H lu -Ala-Lys(X)-Cys(Y)-Arg(Z)-Lys(X)-Arg(Z) Ill -RESIN 
lAmidation 
o NH- CH,,-CH,,-CH:;-CH:;-~H 0 
A-N Hi -A 13-LYS(~-CYS( :l-A rg(Z)-Lys( Xl-A rg( Z) 
A, Intercalator-linker A; P, Phthaly l; X, Boc; Y, Trt ; Z, Pbf 
Figure 35 Protocol Adopted in Constraining Peptide Conjugate 9A 
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In the ftrst step of the protocol the N-terminal was se lect ively deprotected and 
acylated with intercalator-linker A to afford 9A using the condit ions described 
previously in section 3.5.3 .1. The carboxyl function of the Glu residue at pos ition 
i was deprotected and amidated with the phthalimide protected diamine linker 
using PyBOP. Removal of the phthalimide group was achieved using 2-+ % 
hydrazine in methanol. The second Glu residue was deprotected and amidation 
was attempted with the free amino entity of the l,4-diaminobutane br idge, The 
peptide conjugate (figure 36) was fully deprotected and cleaved from resin using 
TFA as described in section 3.2.5. 
Figure 36 Peptide Conjugate 9A 
Analys is of peptide conjugate 9A using MALDI-MS. howe\'er ind icated that the 
desired product had not been iso lated. There are two po ssible e :--:p lanations fo r the 
h ' I'.e , peptl'de cha in aggregat ion and stc.' ric fa ilure of this particular synt eSlS. - ~ -
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hindrance. The former arises from either hydrophobic interactions or interchain 
hydrogen bonding and often results in incomplete coupling and deprotection. This 
is however is unlikely as acylation of peptides 1-8 occurred satisfactorily. Steric 
hindrance is created by the bulky nature of the side-chain functionalities of the 
amino acid residues and their respective protecting groups. It is highly probable 
that the large Pbfprotecting group used to mask the Arg residue (at position i +6), 
the Trt Cys protection and the Boc protecting group of the Lys residue prevented 
the coupling of the Glu residue to the free amino group of the butyl bridge. If 
indeed these groups are preventing closure of the constraining butyl bridge, it is 
likely that the bridge would mask the critical KCR functional moiety of the peptide 
were closure achieved and hence disrupt DNA binding of the peptide. For these 
reasons this approach was no longer pursued. 
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4 EVALUATION - RESULTS AND DISCUSSION 
The peptides and fmal conjugates synthesised were evaluated both biologically 
and structurally using the techniques described in chapter 2. For convenience, 
table 5 provides a summary of the compounds evaluated. 
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4.1 Biological Evaluation 
Spectrophotometric and fluorescence techniques as described in section 2.2 were 
employed to determine the nature of binding and the affinity of the peptide 
conjugates, shown in table 5, for calf thymus DNA. 
4.1.1 Spectroscopic Studies 
The spectral changes in the absorption characteristics of each conjugate upon 
binding DNA were measured and the spectra of solutions containing a fixed 
concentration of peptide conjugate and varying concentrations of DNA were 
superimposed to determine the presence of an isosbestic point, which is indicative 
of a DNA-binding interaction [52]. As discussed earlier in 2.2.2 the appearance 
of an isosbestic point occurs only where there is a single spectroscopically distinct 
bound form of the drug molecule in addition to the free drug (in solution) and 
where the spectra of free and bound drug superimpose. None of the conjugates 
tested in this study showed an isosbestic point, for example figure 37 shows the 
absorbance spectrum of peptide conjugate IA. This meant that the binding 
affinity of these drugs could not be determined using the method of Scatchard in 










200.00 340.00 480.00 620.00 760.00 900.00 
Wavelength (nm) 
Figure 37 An UV-VIS Absorbance Spectrum to show the Effect of DNA on the 




The lack of spectral shifts and negligible decrease in extinction coefficient on 
interaction of the conjugates with calf thymus DNA could suggest that these drugs 
were not intercalating. However, an isosbestic point as a result of drug-DNA 
intercalation will not be observed if the spectra of free and bound forms of the 
drug do not cross when superimposed. Indeed, it has been previously shown that 
some drugs, for example proflavine, which are known to intercalate into DNA 
[75] do not show an isosbestic point [34]. An isosbestic point is only indicative of 
a single spectroscopically distinct bound form of the drug and not a requirement 
of intercalation. Hence the absence of an isosbestic point in this study does not 
necessarily eliminate intercalation as a mode of binding. 
The results, however, do suggest that intercalation is not the only mode of binding 
exhibited by the conjugates and that it is possible that a second interaction 
between the conjugates and DNA may also be occurring. This mode of binding, 
known as 'external binding', is due to an electrostatic interaction between the 
cationic drug molecules and the polyanionic DNA sugar-phosphate chains [32]. 
External binding of the conjugates is highly plausible as the peptidic moiety of 
these drugs is very basic and therefore electrostatically compatible with the 
backbone of DNA. It is important to note that both intercalation and external 
binding of drugs upon complexation with DNA are dependent on ionic strength 
[32,52]. External binding can be eliminated experimentally by increasing the 
concentration of salt and hence ionic strength. Since the design principle of these 
conjugates requires a mixed mode of binding, that is, interaction of the 
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chromophore and surface binding of the peptide, inhibition of external binding 
was not desirable. For this reason, low salt concentrations (low ionic strengths) 
were used in these investigations. 
The lack of intercalation observed with the conjugates is actually desirable as it 
suggests that the DNA binding affinity of the peptide is greater than that of the 
intercalating chromophore and that it is the peptidic moiety that governs DNA 
binding of the conjugate and hence potentially aids selectivity. This is further 
supported by the studies conducted by Gandecha [57], in which intercalators 1-[2-
(hydroxyethylamino )ethylamino ]anthracene-9, 10-dione (1) and ametantrone (III) 
(see table 6) were shown to bind DNA, through intercalation, with a high affinity 
(1.03 x 106 M-1 and 2.8 x 106 M-1 respectively). Since the intercalator-linkers 
synthesised in this study are similar to those described in table 6, it can be 
assumed that as separate entities these moieties are likely to bind DNA in a 
similar manner, however upon attachment of a peptide fragment DNA binding of 
the chromophore is governed by the latter. It is also plausible that the lack of 
intercalation observed with the conjugates may also be due to the substitution 
pattern of the intercalating chromophore, as it has previously been established that 
mono-substituted anthraquinones bind DNA with a lower affinity compared to 
their bis-substituted analogues [57,76,77]. This is also apparent from the binding 
affinities of the intercalator-linkers described previously and shown in table 6. 
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It is, however, possible that the intercalative binding of the conjugates IS 
considerably diminished where the peptide moiety stabilises the double helix, 
through an electrostatic interaction, by binding DNA in a way that prevents the 
unwinding of the double helix and hence intercalation of the drug. Although this 
form of interaction with DNA is favourable in that it stabilises the duplex and 
hence prevents transcription, it is problematical in that it shows no selectivity for 
the AP-l site. 
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Table 6 DNA Binding Properties of Mono- and Bis-Substituted 
Antbraquinones [57,76] 
R *Binding Affinity 
Constant (K MI) 
1.03 X 106 
1.48 X 106 




* A constant determined by spectrophotometric titration of drug with calf 
thymus DNA; ** The difference between the melting temperature of calf 
thymus DNA in the presence and absence of drug at 10:1 DNA-drug ratio. 
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4.1.2 Fluorescence Studies 
Fluorescence enhancement studies using ethidium bromide as a fluorescent probe 
[34,55,56] were conducted to characterise the interaction between the peptide 
hybrids and calf thymus DNA. Conjugates of peptides 4 and 7 were tested using 
this form of spectroscopy since they exhibited the greatest activity i.e. ability to 
inhibit the AP-l protein binding to its DNA consensus sequence (described later 
in section 4.1.4). Displacement of ethidium bromide from calf thymus DNA by 
the peptide conjugates 4A, 4B, 4C, 4G, 7 A, 7B, 7C and 7G was investigated as 
described by Gandecha [57]. For each peptide conjugate a plot of fluorescence 
intensity against ethidium bromide:DNA ratio was constructed and in each case 
the fluorescence enhancement of ethidium was compared with that obtained for 
DNA in the absence of the drug. 
The fluorescence enhancement of ethidium bromide was diminished with all the 
conjugates. Of the eight conjugates tested, 7C, 4G and in particular 7 A showed 
the maximal displacement of ethidium bromide whereas 4A and 4C exhibited the 
least effect. Figures 38, 39 and 40 show the effects of peptide conjugates 4C. 7 A 
and 7C on the fluorescence of ethidium bromide bound to DNA respectively and 
table 7 shows the percentage of fluorescence quenching (maximum) obtained with 
all the peptide conjugates analysed. The displacement of intercalated ethidium 
bromide from DNA by the peptide conjugates indicates that, to some extent. these 
drugs are binding to the same intercalation site. However the small decrease 
observed in the fluorescent enhancement of ethidium bromide \vith the conjugatc~ 
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suggests that these agents are not very effective in competing for the DNA 
ethidium binding sites, either through lack of intercalation or through differing 
sequence selectivities. Since ethidium shows a preference for GC binding sites 
[32,34], it is possible that the peptide conjugates, like amsacrine [78] and some 
1 ,5-substituted anthraquinones [76,77] are AT specific. 
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Figure 38 Effect of Peptide Conjugate 4C on the Fluorescent Enhancement of 





• Ethidium BromidelDNA 
7 • 7 AlEthidium BromidelDNA 
o 
o 0.1 0.2 0.3 
Ethidium Bromide:DNA Ratio 
Figure 39 Effect of Peptide Conjugate 7A on the Fluorescent Enhancement of 
Ethidium Bromide Bound to DNA (see 6.4.2 for experimental conditions) 
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Figure 40 Effect of Peptide Conjugate 7C on the Fluorescent Enhancement of 
Ethidium Bromide Bound to DNA (see 6.4.2 for experimental conditions) 
132 
Chapter Four 





















*Refer to table 5 for peptide conjugate structures; **Determined from the 
addition of ethidium bromide aliquots to solutions containing i) DNA only 
and ii) DNA and peptide conjugate - the % of fluorescence quenched was 
determined from the maximum fluorescence of ethidium bound to DNA in 
the absence of drug and of ethidium bound to DNA in the presence of drug; 
See 6.4.2 for experimental conditions. 
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4.1.3 Thermal Denaturation Studies 
Thermal denaturation, that is, unwinding of DNA in the presence of a drug leads 
to changes in the absorbance characteristics, as discussed earlier in 2.2.4. which 
can be monitored spectroscopically [58,59]. This phenomenon is used as an 
indicator of a druglDNA affmity [58,59]. Figure 41 shows the melting curve of 
DNA in the presence of peptide conjugate 7 A. The effect of the peptide 
conjugates on the thermal denaturation of calf thymus DNA at a drug to DNA 
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Figure 41 Thermal Denaturation of DNA in the Presence of Peptide Conjugate 
7A (see 6.4.3 for experimental conditions) 
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Table 8 The Effect of Peptide Conjugates on the Melting Temperature of 
Calf Thymus DNA 
**ATm °C 
*Peptide *lntercalator-Linker 




4 5.5 5.6 4.8 3.9 
5 7.3 6.3 
6 10.3 5.9 
7 9.0 5.0 8.5 7.8 
8 6.0 8.5 
*Refer to table 5 for peptide sequences and peptide conjugate structure; 
**ATm is the difference between the melting temperature of calf thymus DNA 
in the presence and absence of peptide conjugate at a 10:1 DNA/drug ratio; 
The melting temperature of calf thymus DNA was found to be 71.0°C (mean 
of duplicate results); The ATm values presented in this table are the mean of 




These results show stabilisation of the DNA double helix to heat denaturation in 
the presence of the peptide conjugates. It is evident that conjugates 6A. 7 A 
(figure 32) and 7C are the most effective where as 4A, 4C and 4G are the least 
effective. 
The ~ T m values of some of the peptide conjugates tested are comparable to those 
of mono-substituted anthraquinones reported in the literature [57,76], (table 6. 
section 4.1.1). However compared to bis-substituted anthraquinones, the peptide 
conjugates are relatively weak intercalators indicating a low affmity of binding to 
DNA. It is important to note, however, that these studies primarily account for 
the binding of the intercalating chromophore of the conjugates and do not 
necessarily give any indication of the affmity of the peptide for DNA. These 
fmdings correlate with those obtained in the fluorescence studies which indicated 
that the peptide conjugates are relatively weak intercalators of DNA. It is possible 
that the peptides, most of which have been shown to bind DNA in a gel 
retardation assay (section 4.1.4), bind strongly to DNA without stabilising the 
double helix. It is interesting to speculate that the difference observed between 
activity in the electrophoretic mobility shift assay (section 4.1.4) which uses an 
AP-1 consensus sequence oligonucleotide and apparently for DNA binding using 
calf thymus DNA arise from the sequence selectivity of the peptides. 
The results from both the thermal denaturation and fluorescence studies sho\\" that 
although the interaction of the peptide conjugates with calf thymus DNA is weak. 
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it is consistent with intercalation. These findings are consistent with those of 
Bailly et al who synthesised anilinoacridine derivatives containing the nucleic 
acid-binding tetrapeptide SPKK and demonstrated that these peptide hybrids 
intercalated into DNA [79]. The weak intercalative properties exhibited by the 
conjugates, synthesised in this study, is desirable as it ensures that the 
intercalating chromophore has the ability to move in and out of the double helix 
through reversible and non-specific interactions, thus aiding selectivity by 
allowing the peptide to effectively search the DNA for the AP-l consensus 
sequence. It is anticipated that upon recognition of the AP-l consensus sequence 
the drug will bind DNA with a greater affmity. 
4.1.4 Electrophoretic Mobility Shift Assay [70] 
Competition assays based on the electrophoretic mobility shift assay (EMS A) 
were conducted in an attempt to detennine the selectivity and ability of the 
peptide conjugates to displace AP-l from its DNA consensus sequence. The 
assays were conducted using cell nuclear fractions containing AP-l family 
binding proteins and with recombinant c-jun homodimers. The EMS A was 
performed in the presence of dithiothreitol (DTT), a reducing agent. as the affmity 
of the fos and jun proteins for their cognate DNA sequences is dependent on the 
reduced state of the specific Cys residue of the highly conserved motif KCR. 
found in the DNA binding domains of these proteins [29]. Reduction of this Cys 
residue generates a free sulphydryl group which permits DNA binding of the AP-
I family of proteins and hence activates transcription and cell growth [11]. Since 
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the KCR motif was incorporated in the peptides employed DTT was also added to 
ensure that the Cys residue of this tri-amino acid sequence was maintained in a 
reduced state to allow DNA binding. 
The extent of inhibition of the AP-l protein by the peptides and their conjugates 
was determined by the intensity of the bands observed in the EMSA using a 
densitometer. The results have been summarised in table 9. A high band intensity 
indicated that the peptides/conjugates had very little or no effect on the 
displacement of the AP-l protein, whereas a low band intensity indicated that the 
peptide/conjugate was an effective inhibitor. 
From the results obtained it was apparent that the peptides were less effective in 
preventing the DNA binding of the c-jun homodimer compared to the peptide 
conjugates, thus suggesting that the intercalating moiety enhances the 
effectiveness of the peptide and hence inhibition of the AP-l transcription factor. 
The results also show that the peptide conjugates containing the more basic 
sequences 4, 5, 6 and 7 were the most effective in displacing the AP-l protein 
from its DNA consensus sequence. In particular peptides 4 and 7 (AKCRNA and 
AKCRKRA respectively) and their respective conjugates exhibited the greatest 
biological activity. Figures 42 shows a typical EMSA of peptide conjugate 7 A in 
which the DNA binding activity of this drug is clearly enhanced with increasing 
drug concentration. Although DTT was added to ensure the Cys residue was 
maintained in a reduced state to permit DNA binding of the peptides it is possible 
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that complete reduction of these moieties was not being achieved. This could 
explain why complete inhibition of the AP-l protein was not observed with any of 




Table 9 The Effect of the Peptides and their ConJ' t h .. uga es on t eDNA Bmdmg 
of the AP-l Protein * [70] 
0/0 Mean Band Intensity** 
Peptide Peptide Conjugate 
Peptide A C D 
1 98 51 
2 99 43 
3 99 41 
4 82 32 
5 83 39 35 42 
6 87 38 34 39 
7 56 26 23 
8 79 56 53 
* Displacement of the AP-l protein from the DNA AP-l consensus sequence 
was determined using EMSA [72]; ** Determined using a densitometer; The 
results are the mean value of two separate EMSAs for each compound. The 
concentrations used were: AP-l = 10.73ng; DNA = 0.108ng = 2.1nM~ Peptide 







Lanes 1 & 10 
Lanes 2-9 







Contain 32P-labelled ON A AP-l consensus seq uence and 
the AP-l (fos/jun heterodimer) protein (HeLa cell 
nuclear extract) with no added peptide conjugate 7 A 
Contain 32P-labelled DNA AP-l consensus sequence 
(2.1nM) with an increasing concentration of peptide 
conjugate 7A (2: 0.21JlM; 3: 0.42JlM ; 4: 0.63~M; 5: 
Figure 42 An Electrophoretic Mobility Shift Assay Showing the Effect of 
Peptide Conjugate 7A on the Displacement of the AP-l Protein form the DNA 
AP-J Consensus Sequence 
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The binding activity of peptides 4 and 7 and their conjugates observed in this 
study correlated with the results obtained from the circular dichroism (CD) and 
molecular modelling studies, which are discussed in greater detail in section 4.2. 
The CD studies suggested that these peptides (i.e. 4 and 7) possess an intrinsic 
propensity to form helical structures, a requirement that seems to be essential in 
allowing tight binding interactions between the AP-1 family of proteins and their 
cognate DNA sequences [21,80-82] (see section 4.2.2). Similarly, molecular 
modelling (see section 4.2.3) indicated that peptides 4 and 7, in particular, were 
more likely to form helical structures and hence bind the DNA AP-1 site with a 
greater affmity compared to peptides 1-3, 5, 6 and 8. Interestingly, displacement 
of the AP-1 protein by peptides 4 (AKCRNA) and 5 (AKCRKA) is similar, 
although it was expected that the substitution of Asn (N) in peptide 4 with Lys (K) 
in peptide 5 would enhance the non-sequence specific electrostatic 
interactions/binding with DNA. Although this seems to be apparent in the DNA 
thermal denaturation studies (see section 4.1.3), the gel retardation assay indicates 




4.2 Structural Evaluation 
4.2.1 NMR Spectroscopy 
4.2.1.1 COSY Experiments 
COSY experiments were performed on all the peptides and their respective 
conjugates in DMSO. Complete structural elucidation using this technique, 
unfortunately was not possible from the spectra obtained. This was due to the 
presence of broad and unresolved peaks thought to be a result of poor 
environmental stability. In addition to this, strong overlapping of resonances, in 
particular those of the ~- and y- protons of the Arg and Lys residues meant that 
not all of the amino acid protons could be unambiguously assigned. Figure 43 
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Figure 43 Partial I H-COSY Spectrum (O-4.5ppm) of Peptide 4 in DMSO (see 
6.5.1 for experimental conditions) 
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Figure 43 Continued Partial' H-COSY Spectrum (3.0-8.5ppm) of Peptide 
4 in DMSO (see 6.5.1 for experimental conditions) 
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Table 10 IH-COSY Assignment of Peptide 4* 
Resonance (ppm) 
NH a ~ y Other 
Ala 8.1 3.9 1.1 
Lys 8.2 4.2 1.6 (1.4) 1.6 2.8 
Cys 8.1 4.3 2.8 
Arg (8.2) (4.2) (1.7) 1.4 3.1 7.0-7.3** 
Asn 8.1 4.4 2.6 
Ala 7.9 4.15 1.3 
*COSY experiments conducted In DMSO (see 6.5.1 for experimental 
conditions); Figures in brackets are not fully resolved; **Guanidinium 
protons. 
4.2.1.2 NOESY Experiments 
NOESY experiments were performed on peptides 4 and 7 were analysed in 
DMSO and trifluoroethanol (TFE). The latter is a helix-inducing solvent, which 
stabilises helices in regions with some a-helical propensity [46,83]. It was 
anticipated that the data obtained from these experiments would establish whether 
these peptides were helical or at least whether they possessed an intrinsic 
propensity to form a helical structure. The spectra generated from the 
experiments conducted in both DMSO and TFE showed no conclusive evidence 
to suggest that the peptides were a-helical, although a correlation signal was 
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observed between the Lys E-protons and the Arg guanidinium group which 
suggested some helicity. 
These results were not entirely unexpected, as it had previously been shown in the 
CD studies, discussed in section 4.2.2, that the peptides only assumed helical 
structures upon transfer to a more hydrophobic environment. Unfortunately the 
spectra of the peptides in TFE also showed no coupling signals that were 
indicative of a-helicity. The lack of order i.e. secondary structure observed in 
these peptides however does not necessarily mean that the peptides are not helical. 
It is reasonable to say that the peptides are helical in TFE as shown in the CD 
studies (section 4.2.2) but the degree of helicity is relatively low, which is why it 
is not apparent from the NOESY experiments. Furthermore, many of the protons 
that might be expected to give cross-peaks (including the Cys SR, Lys NH2 and 
Arg guanidinium group) undergo exchange with the deuterated TFE. 
4.2.2 Circular Dichroism Studies [84] 
Circular dichroism of peptides 4 and 7 and their corresponding conjugates were 
conducted by a research colleague [84]. It was anticipated that the peptides 
employed in this study would either adopt a-helical conformations or appear as 
random coils. A high degree of he Ii city was not expected since one a-helical tum 
incorporates approximately 3.6 residues [44} and the peptides under investigation 
were only of 5-7 residues in length. CD of the peptides and their conjugates was 
measured in 80% TFE/water and 1000/0 TFE at 20°C. The spectra recorded in the 
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more aqueous environment were indicative of a random coil structure rather than 
an a-helical conformation. This was suggested by the band at 195nm which is 
characteristic of random coiling and also by the absence of the two distinct bands 
normally observed at 208 and 222nm which signify a-helicity [66]. The latter 
two bands, however were observed in the spectra of the peptides and their 
respective conjugates in 100% TFE (figure 44), thus suggesting that these 
peptides possess an intrinsic propensity to form helical conformations in 
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On the basis of the results obtained it can be concluded that both peptides 4 and 7 
and their corresponding conjugates are predominantly random coil in aqueous 
solution, although some helical structure is observed upon transfer to a more 
hydrophobic environment. The lack of helical structure observed in an aqueous 
environment in these experiments does not preclude these peptides from adopting 
an a-helical conformation upon binding DNA. These results correlate with those 
obtained from studies of the basic regions of the bZip proteins for example GCN4, 
which in the absence of DNA exist predominantly in a random coil conformation 
with some helical tendencies. However upon binding to DNA, a more 
hydrophobic environment, these regions have been shown to assume a-helical 
structures [20,80-82]. The lack of helicity observed from the CD and NMR 
studies is due to size and also quite possibly to the absence of the DNA AP-l 
consensus sequence which may be an important factor in inducing a-helicity 
[20,80-82]. 
4.2.3 Molecular Modelling 
Insight II, a software program from Biosym Technologies was employed to 
conduct theoretical studies on the peptides and their interactions with the DNA 
AP-l consensus sequence using the amber and cvff forcefields. Energy 
minimisations were performed on the peptides in an aqueous environment, both in 
their extended and helical conformations and also when complexed \\ith the DNA 
AP-l consensus sequence. It was anticipated that the energies obtained from 
these calculations would allow (i) the energy change for transformation of the 
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the peptide from its extended form to its a-helical binding conformation and (ii) 
the energy change for the interaction of the helical peptide with DNA. In other 
words, the energies obtained from these studies can be used to establish the likely 
conformation of the peptides and also determine whether the interaction between 
these peptides and the DNA AP-l consensus sequence is favourable. The results 
acquired from these calculations are summarised in table 11. 
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Table 11 Calculated Energies of AP-l Consensus Sequence Peptides in an Aqueous Environment (kcal mOri) 
-'--
--
*Energy Calculations ***Conformer Peptide 
1 2 3 4 5 6 7 8 
ARCKA AKCRA AKSRA AKCRNA AKCRKA AKCRNRA AKCRKRA AAKCRAA 
c::J c=J r-=-::-
Peptide Potential Energy Extended 18.01 44.36 38.34 58.32 61.76 52.15 -22.70 44.51 
Bound (H) 124.94 40.83 36.28 55.71 51.22 54.64 -22.89 60.31 
Peptide Solvation Extended -202.91 -233.23 -231.51 -242.89 -248.89 -245.54 -269.57 -248.14 
Energy 
Bound (H) -219.96 -189.66 -191.58 -203.77 -207.01 -214.88 -248.82 -252.34 
Extended to Helix 89.88 40.04 37.87 35.73 31.34 33.16 20.56 11.55 
Transformation** 
Interaction Energy with Bound (H) -576.63 -609.23 -607.83 -615.35 -611.95 -594.08 -612.23 -577.39 
AP- t Oligonuleotide 
Relative Solvation AP-t DNA -2.4 29.95 40.95 30.19 43.24 3.61 45.19 5.34 
Energy in Complex 
Bound (H) 104.38 98.58 89.37 90.04 88.22 104.04 67.77 100.79 
Binding Energ~' -474.65 -480.7 -477.51 -495.12 -480.49 -486.43 -499.27 -471.26 
Calculated using an RMS derivative ofO.OOlkcal/mol and 5000 iterations; ** In solution; *** Peptide conformation; (H), Helical; 
,\ = Ala C=(\s K = Lys N = Asn R=Arg S = Ser 
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It is apparent from the energies obtained that the heptamers, that is, peptides 7 and 
8 are more likely to adopt a-helical structures, although in each case this process 
does not seem to be spontaneous. Peptide six which is also a heptamer however 
seems to require greater energy than peptides 7 and 8 to form a helical structure. 
This is thought to be due to the presence of an Asn residue which is known to 
disrupt a-helices because its side chain contains both a hydrogen bond donor and 
acceptor in close proximity to the peptide backbone, where they compete for the 
main chain NH and CO groups [85]. In general the binding energies of the 
peptides are similar and suggest that the interaction of these peptides with the 
DNA AP-l site is spontaneous and hence favourable. Figure 45 shows the 
interaction of peptide 7 with the DNA AP-l consensus sequence. From the results 
shown in table it can be deduced that peptides 4 and 7 are the two most strongly 
binding peptides. This correlates with the experimental [mdings using the EMSA 
(section 4.1.4). The next most affmic AP-l peptide is 6, which has a binding 
energy 8.7kcal mor l (36.5 kJ mor l ) lower than that of 4. Peptides 4 and 7 also 
show the strongest interaction energy with the DNA AP-l consensus sequence 
(table 11). Aside from this, no clear pattern emerges from the molecular 
modelling data. 
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Figure 45 A Computer model of Peptide 7 Complexed witlt tlt e DNA A P-/ 
COllsensus Sequence (see 6.5.3 for experimelltal details) 
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Energy minimisations were also performed on peptide 9 in its constrained form 
when complexed with the AP-l site (figure 46). The binding energy obtained 
from this calculation was -422.39kcal mor). From this energy value, it is 
apparent that the interaction between this peptide and DNA is not as spontaneous 
as that between the AP-l site and the unrestrained peptides, the binding energies 
of which ranged between -474 to -500kcal mOrl. The difference in the binding 
energies of the unrestrained peptides and the constrained helical peptide was 
attributed to the presence of the alkanediamine bridge, which seemed to be 




Figure 46 A Computer Model of Peptide 9 (see 3.7, figure 34, for peptide 
sequence) Complexed with the DNA A P-l COJ1sellsus Sequellce (See 6.5.3 for 




It can be concluded that the results obtained from the structural analysis of the 
peptides and the conjugates correlate with those from the biological studies. 
Experimental studies show that conjugates of peptides 4 and 7 are particularly 
effective in preventing the DNA binding of the c-jun homodimer (see section 
4.1.4). The greater activity exhibited by these peptides may be attributed to the 
ability of the peptide moieties to form helical structures, which seem to be an 




5 SUMMARY AND CONCLUSION 
The use of synthetic peptides with an ability to recognise and bind to specific 
sequences of DNA has long been considered a useful probe to study the 
mechanism of gene expression and to potentially control transcription [79,86,87]. 
Based on this concept several intercalator-linked peptides, bearing the KCR motif 
found in the DNA binding domains of the AP-l transcription factor were 
successfully synthesised. Biological analysis of these peptide conjugates 
demonstrated that short peptide fragments of 6-7 residues were capable of 
preventing the DNA binding of the AP-l protein and hence potentially controlling 
transcription. Analysis of these conjugates using spectroscopic techniques 
established that they were weak intercalators of DNA and hence suggested that 
the DNA binding affmity of these potential transcription factors was governed 
principally by the peptide moiety. It is anticipated that the greater DNA binding 
of the peptide over the intercalating moiety would aid selectivity. 
It is likely that both the inhibition of the AP-l protein and selectivity of the 
peptide conjugates may be enhanced by incorporating the entire sequence found 
in the DNA binding domains of the fos and jun proteins including the second 
DNA binding chain found in the native fos/jun dimers. Since this work began, 
this approach has been described by Tabor [88] and Takenaka et al [89]. Both 
workers described the synthesis of GCN4 (the yeast equivalent of the AP-l) 












PEPTIDE = DP AALKRARNTEAARRSRARKLQRM 
Figure 47 GCN4 Intercalator Hybrid Peptides I [88}, II [89} 
Compound (I), synthesised by Tabor [88] consists of the N-terminal basic region 
of the GCN4 transcription factor with a Gly-Gly-Cys motif added at the C-
terminus to enable dimerisation via disulphide bond formation. This peptide was 
then attached to 9-chloroacridine via an ll_aminoundecanoic linker and t\\O 
further glycine (Gly) residues. The peptide moieties in compound (11) also mimic 
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the basic region of GCN4. In this case however the peptides were connected to 
1 ,8-bis[[ 4-(3-aminopropyl)piperazinyl]propylamino ]-9,1 O-anthraquinone to give a 
dimeric model peptide. Takenaka et al [89] observed both a sequence specific 
interaction and increased a-helicity in the peptide moieties of (II) upon binding 
DNA using Circular Dichroism studies. Interestingly the biological evaluation of 
these peptide hybrids has not yet been reported. This may be because although 
the approach undertaken by Tabor [88] and Takenaka [89] would be useful in 
principle, it is unlikely to have practical application. Incorporation of the entire 
sequence found in the DNA binding domains of the fos and jun proteins, 
including the second chain, would possibly maximise the selectivity of an AP-l 
inhibitor, but in doing so it would most likely create a number of difficulties. In 
the first instance, the task of synthesising such a large mo lecule and its 
management is likely to be difficult both in terms of purification and solubility. 
Secondly, the biological stability of such a large compound would be 
problematical, in particular because, the peptide chains would be readily 
susceptible to enzyme hydrolysis. Thirdly, cellular and nuclear localisation of 
these bulky molecules would be unlikely. 
Unlike the work reported by Tabor [88] and Takenaka [89], the studies conducted 
in this project have demonstrated that peptide conjugates with relatively short 
linkers and peptide fragments containing the critical KCR motif are capable of 
inhibiting DNA binding of the AP-l protein and also that incorporation of the 
• .sc: d· th DNA binding domains of the AP-l transcription entIre sequence loun ill e 
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factor is not necessarily required. In addition to inhibiting the binding of the AP-l 
protein, the peptide conjugates are designed to be subject to redox regulation. 
This, in principle, ensures that inhibition of the AP-l protein occurs only in cells 
under oxidative stress and anticipates therefore that the drug has very little or no 
effect on the transcription of normal healthy cells. The selectivity of these AP-l 
inhibitors for tumours in oxidative stress where cellular oxygen and or reducing 
thiols are depleted however remains to be investigated. 
5.1 Future Work 
Further studies are required for a more extensive biological and structural 
evaluation of the peptides and their conjugates. Future works would include i) 
determining the DNA binding of the conjugates under oxidative conditions, i.e. 
determine the selectivity of the peptide conjugates for tumour cells under 
oxidative stress; ii) establish the binding affmity of the peptide conjugates for the 
DNA AP-l consensus sequence and fmally iii) measure the helical content of the 
peptides upon binding the DNA AP-l consensus sequence using circular 




The IH_ and 13C-NMR spectra were recorded on a 250MHz super-conducting 
Bruker AC250 Spectrometer at 303.3K unless otherwise stated. Infrared spectra 
were recorded in nujol muls or potassium bromide on a Perkin-Elmer 683 
Spectrophotometer. The mass spectra were recorded on a VG 70 SEQ 
spectrometer and MALDI-MS was performed usmg a Finnigan MAT Laser 
Desorption spectrometer. The elemental analysis was conducted at the 
Microanalytical laboratory at Manchester university. 
Melting points were determined on a hot stage microscope and are uncorrected. 
Thin layer chromatography was performed on silica gel plates and was monitored 
sequentially with UV light and iodine powder; ninhydrin spray and bromocresol 
green were employed to stain amino and carboxyl groups respectively. Silica gel 
60 (220-440 mesh) was employed where column chromatography was used. 
6.1 Synthesis of Intercalator-Linkers 
Synthesis of 1-[N-{2-Aminoethyl}amino]anthraquinone 
I ChI hr · (250 I.Ommol) was dissolved m excess - oro ant aqumone mg; 
ethylenediamine (5g; 0.083mol) and was left to stir at room temperature under 
nitrogen for 72hrs. The reaction mixture was diluted with water (lOOm!) to yield 
. . . I hromatography eluting with a red precipitate. ThIS was purIfied usmg co umn c .. 
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dichloromethane and an increasing concentration of methanol (0 500 ) '.' h - '0, gl\ mg t e 
product as a red solid (100mg; 36.5%); Mpt 148°C: vrnax!cm-1 3350 (NH
2
), 2590 
(CH), 1690 (C=O), 1600 (C=C), 1280 (NH), 700 (ArCH); bH (CD)OD): 3.0 (m, 
2H; CH2NH2), 3.5 (t, 2H; NHCH2), 7.25 (d, 1H; ArH), 7.5 (m, 2H; ArH), 7.8 (m, 
2H; ArH), 8.15 (d, 2H; ArH), 8.3 (d, 1H; ArH); be (CD30D): 41.86. 43.25, 
116.67, 119.31, 127.0, 127.77, 134.29, 135.01, 136.55, 144.5, 181.5, 183.27; III Z 
+ 
(M + H) 267; CHN: Found C (68.99%) H (5.33%) N (9.82%), Calculated with 
0.75 H20, C (68.690/0) H (5.550/0) N (10.02%) 
Synthesis of 1-[N-{2-Succinamidylethyl}amino]anthraquinone 
1-(N-{2-Aminoethyl } amino )anthraquinone (lOOmg; 0.37mmol) and SUCCInIC 
anhydride (37.5mg; 0.45mmol) were dissolved in DMF (10ml) and left to stir for 
3hrs under nitrogen at room temperature. The reaction mixture was diluted with 
water (50ml) and the product was extracted with dichloromethane (3 x 25ml). 
The organic layers were dried over MgS04 and reduced in vacuo. The product 
was chromatographed, eluting with dichloromethane and an increasing gradient of 
methanol (0-500/0) and was isolated as a red solid (l37.5mg; 72%); Mpt 156°C: 
Vrnax!Cm-1 3400 (COOH), 3300 (NH), 2900 (CH), 1710 (C=O), 1680 (NHC=O), 
1630 (C=C), 1280 (NH), 700 (ArCH); bH (DMSO): 2.4 (m, 4H; NHCH:C 'H_,NH2), 
3.2 (t, 2H; COCH2), 3.4 (t, 2H; CH2COOH), 7.3 (d, 1H; ArH), 7.4 (d, 1 H: ArH)' 
7.8 (m, 2H; ArH), 8.1 (m, 2H; ArH), 9.7 (1: 1 H; ArH); be (DMSO): 40.25 113.0, 
115.29,126.38,126.54,132.46,134.14,134.5,134.63, 135.71. 151.01, 151.67, 
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183.01, 184.0; mJz (M + Ht 367; CHN: Found C (64.93%) H (S.04%) N 
(7.S6% ), Calculated 0.75 H20, C (64.780/0) H (4.99%) N (7.S6%) 
Synthesis of 1-[2-{N-(2-Aminoethyl]succinamidyl}ethyl)amino]anthraquin one 
Ethylenediamine (16mg; 0.27mmol), PyBOP (l42mg; 0.27mmol) and DIEA 
(47/-11; 0.27mmol) were added to 1-[N-{2-lsuccinamidylethyl }amino]-
anthraquinone (100mg; 0.27mmol) in DMF (l5ml). This was then left to stir at 
room temperature, under nitrogen for 3hrs. The reaction mixture was reduced In 
vacuo and the product was chromatographed with an eluent of dichloromethane 
and an increasing gradient of methanol to yield a red solid (19mg; 17%): Mpt 
171°C; vmax/cm-1 3300 (NH2), 3050 (ArCH), 2980 (CH), 1680 (NHC=O, C=O), 
1600 (C=C), 1290 (NH), 720 (ArCH); bH (CD30D): 2.2 (s, 4H; COCH2CH2CO), 
3.0 (t, 4H; ArNHCH2CH2) , 3.4 (m, 4H; HNCH2CH2NH2), 7.3 (m, 2H: ArH), 7.6 
(m, 1H; ArH), 7.9 (m, 2H; ArH), 8.1 (m, 2H; ArH), 9.7 (m, IH; NH); 8c 
(DMSO): 35-45, 115.17, 118.59, 126.25, 126.43, 133.44, 133.99, 134.37, 134A9, 
135.56, 151.42, 17l.49, 172.09, 182.88, 183.91; m1z (M + Ht 409; CHN Found 
C (6l.56%) H (5.89%) N (12.79%), Calculated with 1.1 H20, C (61.71
0
0) H 
(6.12%) N (13.09%) 
Synthesis of 1_[N_{2_(2_Succinamylethyl)succinamidyl}etbylaminolanthra-
quinone 
Succinic anhydride (73mg; 0.73mol) was added to 
. . ' . hr' (') SOm o ' 061 mol) in DMF 
ammoethyl)succmamldyl}ethylammo]ant aqumone - b" 
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(5ml) and left to stir for 18hrs under nitrogen at room temperature. The reaction 
mixture was diluted with water (25ml) to yield a red precipitate which was 
isolated by filtration. This was then chromatographed with an eluent of 
dichloromethane and an increasing gradient of methanol (30-100%) and was 
isolated as a red solid (80mg; 25.7% ); Mpt 241°C; vrnax/cm-1 3450-2400 (COOHt 
3300 (NH), 3050 (ArCH), 2910 (CH), 1680 (NHC=O, C=O), 1570 (C=C). 1300 
(NH), 700 (ArCH); bH (CD30D): 2.5 (t; (CH2hNHCO; NH(CH2hNH:J, 3.2 (t; 
(7.7, m; ArH2), (8.2, d; ArH), (8.3, d; ArH); be (DMSO): 35-40, 112.30, 115.19, 
126.29, 126.50, 133.41, 133.49, 134.04, 134.44, 134.58, 135.65, 151.51, 171.53, 
172.14, 172.49, 182.98, 183.95; m/z (M + Ht 509; CHN Found C (59.91%) H 
(5.210/0) N (10.45%), Calculated with 0.7 H20, C (59.93%) H (5.64%) N 
(10.75%) 
Synthesis of 2_[N_{2_Hydroxyethyl}-N-methylaminolethylamine 
Method A 
2-Bromoethylamine hydrobromide (30g; 0.15mol) was added slowly to 2-
(methylamino )ethanol (54. 9g; O. 73mol) under nitrogen at room temperature, after 
. . t tralised 
which the reaction was refluxed for 5hrs. The reactIOn mIX ure was neu 
using 50% NaOH and the desired product was isolated by fractional distillation at 




N-Methylenediamine (8.14g; O.llmol) and boron trifluoride etherate (1.12!!: 
0.011mol) were added to benzophenone (20g; 0,11mol) in xylene (50ml). This 
was refluxed for 20hrs and the water produced during the reaction was removed 
using a Deane-Starke apparatus. The solvent was removed in vacuo to afford the 
desired product (24.6g; 0.103mol) which was used without further purification. 
Ethylene oxide (11.32g; 0.26mol) was then added to the benzophenone protected 
amine in methanol (50ml) at O°C and refluxed using a condenser and a cold 
finger. The benzophenone protecting group was then removed by stirring the 
product with hydrochloric acid (1 OOml; 5M) for 18hrs at room temperature. 
The reaction mixture was washed with dichloromethane (3 x 50ml) and then 
neutralised with sodium hydroxide. The product was finally extracted with 
dichloromethane (3 x 50ml) after which the organic layers were combined, dried 
over magnesium sulphate and then reduced in vacuo. The product was isolated as 
a yellow oil (7.8g; 60.2%) after purification by fractional distillation at 80°C at 
1mmHg; yrnax!cm-1 3300 (OH, NH2), 2850 (CH), 1300 (NCH3); DH (CDCh): 2.2 
(s, 3H; NCH
3
), 2.4 (m, 4H; CH2N(CH3)CH2), 2.7 (t, 2H; NH2CH2), 3.5 (t. 2H; 
CH
2
0H); Dc (CDCb): 40.18,42.13,58.81,59.12,59.81; mlz (M + Ht 119 
167 
Chapter 6 
Synthesis of 1-[2-{N-(Hydroxyethyl)-N-methylamino}ethylaminolanthra_ 
quinone 
l-Chloroanthraquinone (2.9g; 0.012mol) and 2-[N-{2-HydroxyethyJ; -N-
methylamino]ethylamine (14.6g; 0.12mol) were refluxed under nitrogen for 2.fhrs. 
The reaction mixture was diluted with water (150ml) and the product was 
extracted with ethyl acetate (3 x 100ml). The organic layers were combined, dried 
over MgS04 and reduced in vacuo. The product was chromatographed, eluting 
with dichloromethane and an increasing gradient of methanol (0-30%) to yield a 
red solid (340mg; 12.2%); Mpt 72°C; Vrnax!cm- l 3400 (OH), 3250 (NH), 2850 
(CH), 1700 (C=O), 1620 (C=C), 1500(CH), 1190 (NCH3), 1270 (NH), 700 
(ArCH); bH (CDCh): 2.4 (s, 3H; NCH3), 2.65 (t, 2H; NHCH2CH2NCH:I), 2.8 (t, 
2H; N(CH3)CH2CH20H), 3.4 (q, 2H; NHCH2CH2N), 3.7 (t, 2H; CH2( 'H20H), 7.0 
(d, 2H; ArH), 7.5 (m, 2H; ArH), 7.65 (m, 2H; ArH), 8.2 (t, IH; ArH), 8.25 (t, 1H: 
ArH); be (CDCh): 40.15, 40.83, 55.98, 59.07, 59.94, 115.70, 117.99, 126.65, 
127.01, 133.04, 133.94, 134.81, 135.01, 135.43, 151.62, 183.88, 184.99; m/z (M + 
Ht 325; CRN: Found C (70.460/0) H (6.26%) N (8.23%), Calculated with 0.025 
H20, C (70.270/0) H (6.180/0) N (8.62%) 
Synthesis of the 1_l2_{N_(Hydroxyethyl)-N-methylamino}ethylaminolanthra-
quinone Hydrochloride 
Ethereal hydrogen chloride (2ml) was added to 1_[2-{N-(hydroxyethyl )-N-
methylamino} -ethyl amino ] anthraquinone (340mg; ) in dichloromethane (5m I) 





Triphenylphosphine (157mg; 0.6mmol) was added to 1-[2-{N-(hydroxy"ethyl)-N-
methyl-amino} ethylamino ] anthraquinone hydrochloride (110mg; O.3mmol) in 
dichloromethane (5ml). This was followed by the addition of carbon tetrachloride 
(276mg; 1.8mmol) after which the reaction was left to stir under nitrogen at room 
temperature for 20hrs. The product was isolated in vacuo and then purified using 
column chromatography eluting with dichloromethane and an increasing gradient 
of methanol (200/0-800/0), giving an orange-red solid (78.6mg; 68%); vrnax!cm- I 
3400 (NH), 2910 (CH), 1690 (C=O), 1590 (C=C), 1295 (NCH3), 720 (Cl), 710 
(ArCH); bH (MeOH) 3.1 (s, 3H; NCH3) 3.55 (t(b), 2H; NHCH2CH2NCHd 3.7 
(t(b), 2H; N(CH3)CH2CH2CI) 3.9 (t, 2H; NHCH2) 4.0 (t, 2H; CH2Cl) 7.3 (d, 1 H; 
ArH) 7.6 (m, 2H; ArH) 7.5 (m, 2H; ArH) 8.2 (dd, IH; ArH) 8.3 (dd, IH: ArH); be 
(CD30D): 38.40, 38.52, 41.77, 56.02, 58.66, 115.39, 118.96, 127.60, 127.85, 
134.66, 135.43, 136.0, 136.11, 136.89, 151.94, 184.66, 186.57; mlz (M + Ht 343 
Synthesis of 9-[S-{Carboxymethyl} mercapto]anthraquinone 
Thioglycolic acid (29mg; 0.56mmol) and DIEA (131mg; 0.56mmol) were added 
to 9-chloroacridine (100mg; 0.468mmol) in methanol (3ml). The reaction was left 
to stir at room temperature, under nitrogen for 18hrs. A precipitate was isolated 
by filtration and then chromatographed with an el uent of dichloromethane and an 
increasing gradient of ethanol (5-50%), giving a yellow powder (98mg; 77.7°oL 
Mpt 2110C; Vrnax/cm- 1 3400-2400 (COOH), 2950 (CH), 2500 (SH). 1690 (COL 
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1580 (C=C), DH (CD30D): 3.7 (s, 2H~ SCH2 ), 7.5 (m, 4H~ ArH), 8.1 (d, 2H; ArHl. 
8.9 (d, 2H~ ArH); Dc (CD30D): 45.30, 127.99, 128.29, 129.85, 132.03, 149.53. 
162.37; mJz (M+) 298 
Synthesis of BocLysine(Fmoc)OH 
Fmoc-N-hydroxysuccinarnide (342rng~ 1.0rnmol) in l,4-dioxane (5ml) was added 
dropwise to BocLysine-OH in 100/0 Na2C03 (5ml) at O°C under nitrogen, after 
which the reaction was allowed to warm up to room temperature and then left to 
stir for 2.5hrs. The reaction mixture was diluted with water (20ml) and washed 
with ether (3 x 10rnl) and dichloromethane (3 x 10ml). The aqueous layer was 
then acidified to pH2 using concentrated hydrochloric acid to yield a white solid 
(250mg~ 52.6%)~ Mpt 62°C~ vrnax/crn-1 3500-2400 (COOH), 3350 (NH2), 2950 
(CH), 1700 (COOR, OCO), 1530 (C=C), 750 (ArCH); bH (CDC!:;): 1.6 (s(b), 
(d(b), 2H; a-CH~ CHCH20), 4.4 (d(b), 2H~ CHCH20), 7.2 (m, -lH; ArH), 7.5 (d, 
2H; ArH), 7.7 (d, 2R; ArH)~ Dc (CDCb): 28.35, 47.29, 66.69, 67.09, 119.99, 
125.07,127.09, 127.15, 141.36, 143.99, 156.70~ mJz (M + Ht 469 
Synthesis of N-( 4-Aminobutyl)phthalimide 
Phthalic anhydride (252mg~ 1.9mol) and l,4-butadiamine (150mg; 1.9mol) \\~r~ 
retluxed in chloroform (30ml) for 5hrs. The reaction mixture was allowed to cool 
and a white solid was isolated. This was purifi~d using column chromatograph~ 
. . . t' th 1 ('\_'\00 ') The with dichloromethane and an mcreasmg gradIent 0 me ano - - o. 
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product was isolated as an off-white solid (75mg' 20.2%)' Mpt 210-20C" -. " . \ rna'\ em 
3400 (NH2), 3100 (CH), 2900 (CH), 1650 (C=O), 1390 (N), 790 (ArCH); bH 
(D20): 1.7 (m, 4H; NCH2CH2CH2), 3.0 (t, 2H; CH2CH2NH2), 3.3 (q, 2H; 
NCH2CH2), 7.4 (m, 4H; ArH); bc (D20): 26.98,28.17,41.81,42.02, 129.C).f. 
130.66, 132.16, 133.12, 182.36; m/z (M + Ht 219 
Synthesis of 9-[2-{Hydroxyethyl}amino]acridine 
9-Chloroacridine (lOOmg; 0.46mmol) was added to excess ethanolamine (lOml; ) 
and left to stir at 80°C for 30hrs. The reaction mixture was diluted with water 
(50ml) to yield a yellow precipitate which was filtered and left to dry in a vacuum 
desiccator. The product was purified using column chromatography with an 
eluent of dichloromethane and an increasing concentration of ethanol (0-30%), 
and was isolated as a yellow powder (43mg; 38.7%); Mpt 196°C; vrnax!cm- I 3495 
(OH), 3310 (NH), 2800 (CH), 1650 (C=C), 750 (ArCH); bH (CD30D): 3.2 (t, ~H; 
NHCH2), 4.0 (t, 2H; CH20H), 6.5 (m, 2H; ArH), 6.8 (m, 1H; ArH), 7.1 (d, 2H; 
ArH), 7.5 (d, 2H; ArH); Dc (CD30D): 42.33, 45.50, 124.96, 125.71, 131.02, 
132.99, 138.06, 167.44; m/z (M + Ht 239 
6.1.1 Attempted Synthesis 
Synthesis of l_IN_{3_Carboxypropyl}aminoJanthraquinone 
I-Chloroanthraquinone (500mg: 2.06mmol), y-aminobutyric acid ( 1.06g: 
10mmol), zinc chloride (28.0mg; 0.2mmol) and 1 M NaOH (lO.3mL 1 Ommo! ) 
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were refluxed in DMSO under nitrogen for 18hrs. The reaction mixture was 
cooled, diluted with water (100ml) and neutralised with concentrated hydrochloric 
acid to yield a red precipitate. Purification of this red solid was unsuccessful. 
The above method was also employed ill the synthesis of 1-(S-
{carboxymethyl }mercapto )anthraquinone and 1-(N-methyl-N-carboxymethyl)-
anthraquinone. 
Synthesis of 9-[N-{Aminoethyl}amino]acridine 
9-Chloroacridine (100mg; 0.46mmol) was dissolved in excess ethylenediamine 
(2.76g; 0.046mol) and was left to stir for 18hrs at room temperature. The reaction 
mixture was diluted with water (25ml) and the product was extracted with 
dichloromethane (3 x 20ml). The organic layers were combined, dried over 
magnesium sulphate and then dried in vacuo. Column chromatography was 
employed to purify the product using dichloromethane with an increasing gradient 
of methanol (10-50%). NMR analysis of the product however indicated that the 
reaction had been unsuccessful. 
Synthesis of 9-[2-{Ethyl-p-toluenesulphonate}amino] acridine 
p-Toluenesulfonyl chloride (142mg; 0.74mmol) was added to 9-[2-
{hydroxyethyl}amino]acridine (100mg; 0.37mmol) in pyridine (2m1) at O°C. The 
reaction mixture was gently swirled and then left to stand at 5°C for 24hrs. The 
mixture was diluted with ice-water and the isolated precipitate was washed with 
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water. The product was purified using column chromatography, however NMR 
analysis of the product suggested that the desired product had not been isolated. 
6.2 Synthesis of the Peptides and their Conjugates 
General Procedures for the Synthesis and Isolation of the Peptides and their 
Corresponding Conjugates 
The peptides synthesised on the NovaSyn Gem synthesiser and those supplied by 
Calbiochem-Novabiochem Ltd were fully protected and bound to resin. The 
DMF was freshly distilled and TF A employed in all reactions was anhydrous and 
ofHPLC grade respectively. All peptides and conjugates were stored at -20°C. 
6.2.1 General Procedure For SPPS 
The resin (l g) was solvated in DMF (lOml) for 4Smin prior to removal of the 
Fmoc protecting group using 20% piperidine in DMF, after which it was washed 
thoroughly with DMF. Activation of the Fmoc protected amino acid residue (4eq) 
was achieved using PyBOP (4eq) and DIEA (8eq) in DMF (Sml) - this cocktail 
was then added to the reaction vessel and left to react with free amino terminal of 
the resin for I-2hr. The excess reagents were then removed by washing the resin 
with DMF and the residue was deprotected using 20% piperidine in DMF. This 
procedure was repeated until the desired peptide sequence had been completed. 
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6.2.2 General Procedure For Solution Phase Peptide Synthesis 
The Fmoc-protected carboxyl component (l.OOg; 2.1mmol), NMM (0.23ml: 
2.1mmol), and EDC (400mg; 2.1mmol) were dissolved in anhydrous THF(50ml) 
under nitrogen and cooled to O°C. The reaction was left to stir for 15minutes after 
which the amino component (290mg; 2.lmmol) was added. The reaction was left 
to stir at O°C for a further 45minutes and then left to stand for 18hrs at 5°C. 
The so lvent was removed in vacuo and the resulting residue was disso lved in 
dichloromethane (1 OOml) and then washed with water (3 x 50ml), potassium 
hydrogen sulphate (3 x 50ml), sodium bicarbonate (3 x 50ml) and sodium 
chloride (3 x 50ml). The organic layers were dried over MgS04 and reduced in 
vacuo. The peptidic intermediates were purified either by column 
chromatography or recrystallisation. 
Fmoc Deprotection 
A 20% solution of piperidine in DMF was added to the resin at room temperature 
under nitrogen. This was left to stir for Ihr. The reaction mixture was then 
filtered and washed sequentially with DMF, acetic acid, dichloromethane and 
ether. The resin was dried in a vacuum desiccator and then stored at -20°C. 
Final Deprotection and Cleavage 
A solution of EDT (50/0), TIS (50/0) and water (5%) in TFA was added to the resin. 
This was left to stand for 5hrs with occasional swirling at room temperature. 
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under nitrogen. The resin was filtered and washed with TF A. The filtrate was 
reduced in vacuo at room temperature. The product was subsequently triturated 
with cold anhydrous ether and the dried in a vacuum desiccator over phophorous 
pentoxide (P20 5). 
6.2.3 Conjugate Synthesis 
The selective and final deprotection and cleavage of all conjugates was achieved 
using the conditions and methods described earlier. In each case prior to 
alkylation and amidation the resin was allowed to swell in DMF at room 
temperature under nitrogen for 45 minutes. 
A - D and H Conjugates 
The intercalator-linked acid (4eq), PyBOP (4eq) and DIE A (8eq) in DMF was 
added to the resin (1 eq) at room temperature under nitrogen. The reaction mixture 
was left to stand for 3hrs with occasional swirling. The resin was washed with 
DMF, ethanol and ether. The resin bound conjugate was dried in a vacuum 
desiccator over P205. 
E and F Conjugates 
The mustard (4eq) and DIEA (8eq) in DMF was added to the resin (1 eq) at room 
temperature under nitrogen. The reaction was left to stand for 3hrs with 
occasional swirling. The resin was washed with DMF. ethanol and ether and then 




BocLys(Fmoc)OH (4eq), PyBop (4eq) and DIE A (Seq) in DMF was added to the 
resin at room temperature under nitrogen. The reaction was allowed to stand for 
3hrs with occasional swirling. The resin was washed with DMF, ethanol and 
ether. The Fmoc group was removed and 1-(N-{2-succinamidylethyl})-
amino )anthraquinone (A) was then attached to the peptide using the method 
employed in the synthesis of the A conjugates. 
D Conjugates 
BocLys(Fmoc)OH (4eq), PyBop (4eq) and DIEA (Seq) in DMF was added to the 
resin at room temperature under nitrogen. The reaction was allowed to stand for 
3hrs with occasional swirling. The resin was washed sequentially with DMF, 
ethanol and ether. The Fmoc group was then removed using the method described 
earlier. 
The addition of BocLysOH was repeated after 1-(N-{2-succinamidylethyl})-
amino )anthraquinone was attached using the method employed in the synthesis of 
the A conjugates. 
6.2.4 Spectral Analysis of the Peptides and their Respective Conjugates 
The peptides and their respective conjugates were analysed using I HNMR and 




8H (1.25~ Ala 13) (1.35~ Ala 13) (1.5~ Arg ,Lys 13, X, Lys 8) (2.7; Lys E) (2.8: Cys p) 
(3.1 ~ Arg 8) (3.9~ Ala a) (4.2~ Ala a) (4.3~ Lys a) (4.4: Cys) (7.0-7.2 Arg 
guanidinium) (7.6~ Arg side-chain (SC) NH) (7.8~ Lys NH (SC)) (8.0~ Ala, Cys) 
(8.1-8.3 Arg, Lys NH)~ mlz (M + Ht 548 
Conjugate lA 
8H (1.2; Ala 13) (1.5-1.6; Arg, Lys p, X, Lys 8) (2.4; linker (L)) (2.75: Lys E) (2.8~ 
Cys 13, L) (3.1; Arg 8, L) (4.0-4.5; Ala, Arg, Cys, Lys a) (7.2-7.6; Arg 
guanidinium) (7.5; Arg NH (SC)) (7.7; Lys NH (SC)) (7.9-8.5; Ala, Arg, Cys, Lys 




(1.2~ Ala 13) (1.35~ Ala 13) (1.5-1.8; Arg ,Lys p, X, Lys 8) (2.7; Lys E) (2.8~ Cys 
13) (3.1; Arg 8) (3.9~ Ala a) (4.2; Ala a) (4.3-4.5; Arg, Cys, Lys a) (7.0-7.2 Arg 
guanidinium) (7.6; Arg (SC) NH) (7.8; Lys NH (SC)) (8.1-8.3: Ala, Cys, Lys 




(1.2; Ala 13) (1.35; Ala 13) (1.5-1.8; Arg, Lys p, X, Lys 8) (2.3: L) (2.75: Lys E) 
(2.8; Cys /3, L) (3.1; Arg /), L) (3.4; Ala a) (4.25: Ala a) (4.3--1-1, Arg, Cvs, L\s 
a) (7.0-7.3: Arg guanidinium) (7.5: Arg NH (SC)) (7.7: L\s NH (SC)) (79-8.5: 




8H (1.1; Ala (3) (1.25; Ala (3) (1.5-1.7; Arg, Lys 13, x, Lys 8) (2.75~ Lys E) (3.1: 
Arg, 8, Ser (3) (3.9; Ala a) (4.15; Ala, a) (4.2-4.4; Arg, Lys, Ser a) (7.0-7.2: Arg 
guanidinium) (7.6; Arg NH (SC» (7.8; Lys NH (SC» (7.9; Ala NH) (8.0-8.5; Ala, 
Arg, Lys, Ser NH); mJz (M + Ht 531 
Conjugate 3A 
8H (1.2; Ala (3) (1.35; Ala (3) (1.5-1.7; Arg, Lys 13, x, Lys 8) (2.3; L) (2.75; Lys E) 
(2.8; L) (3.1; Arg, 8, Ser 13, L) (3.9; Ala a) (4.2-4.4; Ala, Arg, Lys, Ser a) (7.0-
7.3; Arg guanidinium) (7.5; Arg NH (SC» (7.8; Lys NH (SC)) (79; Ala NH) (8.0-
8.5; Ala, Arg, Lys, Ser NH; Ar) (9.5; NH); mJz (M + Ht 879 
Peptide 4 
8H (1.1; Ala (3) (1.2; Ala (3) (1.3-1.7; Arg ,Lys 13, X, Lys 8) (2.6; Asn 13 ) (2.75; Lys 
E) (2.8; Cys (3) (3.1; Arg 8) (3.9; Ala a) (4.15; Ala a) (4.2; Arg, Lys a) (4.3; Cys) 
(4.4; Asn) (7.1-7.3 Arg guanidinium) (7.6; Arg NH (SC)) (7.8; Lys NH (SC)) 




(1.2; Ala (3) (1.3-1.6; Arg, Lys 13, x' Lys 8) (2.4; L) (2.6; Asn 13 ) (2.75: Lys E) 
(2.8; Cys 13, L) (3.1; Arg 8, L) (3.4; L) (4.05; Ala a) (4.2; Ala a) (4.3-4-L Arg, 
Cys, Lys ex) (4.45; Asn ex) (7.0-7.4; Arg guanidinium) (7.5; Arg NH (SC)) (7.6; 
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Lys NH (SC)) (7.9~ Ala NH) (8.0-8.3~ Ala, Arg, Cys, Lys, Ar CH) (9.75; NH); 
m/z (M + H)+ 1009 
Conjugate 4D 
OH (1.15; Ala~) (1.2; Ala~) (1.4-1.6; Arg, Lys~, X, Lys 0) (2.3-2.4; L) (2.5; Asn 
~) (2.7-2.8; Cys ~,Lys E, L) (2.9; L) (3.1; Arg 0, L) (3.3; L) (4.1; Ala a) (4.2-4.~: 
Ala, Arg, Cys, Lys a, L) (4.5; Asn a) (7.1-7.4; Arg guanidinium) (7.6; Arg NH 
(SC)) (7.7; Lys NH (SC» (7.8; Ala NH) (7.9-8.3; Ala, Arg, Asn, Cys, Lys, Ar 
CH) (9.75~ NH); mJz (M + Ht 1137 
Conjugate 4F 
OH (1.1; Ala~) (1.3-1.6~ Arg, Lys f3, x, Lys 0) (2.5~ Asn f3, L) (2.7-2.8; Cys f3, Lys 
E) (2.9~ L) (3.1 ~ Arg 0, L) (3.8~ L) (4.1; Ala a) (4.2-4.4; Ala, Arg, Cys, Lys a) 
(4.5~ Asn a) (7.0-7.5; Arg guanidinium) (7.5~ Arg NH (SC» (7.8; Lys NH (SC)) 
(7.9; Ala NH) (7.9-8.3; Ala, Arg, Asn, Cys, Lys, Ar CH); m/z (M + Ht 1122 
Conjugate 4H 
OH (1.1; Ala~) (1.1; Ala f3) (1.4-1.8; Arg, Lys f3, x, Lys 0) (2.6; Asn~, L) (2.8; 
Cys ~, Lys E) (3.1; Arg 0, L) (3.5; L) (3.8; Ala a, ) (4.1; Ala a) (4.2-4.4; Arg, 
Cys, Lys a) (4.5; Asn a) (7.1-7.3; Arg guanidinium) (7.5; Arg NH (SC)) (7.7; Lys 





OI-I (1.2~ Ala 13) (1.35~ Ala 13) (1.5-1.7~ Arg ,Lys 13, X, Lys 0) (2.7-2.8: Cys 13, Lys 
E) (3.1~ Arg 0) (3.9~ Ala a) (4.2~ Ala a) (4.3-4.5~ Arg, Cys, Lys a) (7.0-7.-+ Arg 
guanidinium) (7.7~ Arg NH (SC)) (7.8~ Lys NH (SC)) (7.9; Ala NH)(8.0-8.5: Ala, 
Arg, Cys, Lys NH); m1z (M + Ht 675 
Conjugate 5A 
OI-I (1.2; Ala 13) (1.3-1.6; Arg, Lys 13, x, Lys 0) (2.4; L) (2.7-2.8; Cys p, Lys E, L) 
(3.1; Arg 0, L) (3.4; L) (4.1-4.5; Ala, Arg, Cys, Lys a) (7.4-7.6; Arg guanidinium) 
(7.5; Arg NH (SC)) (7.6~ Lys NH (SC)) (7.7-8.2; Ala, Arg, Cys, Lys NH, ArCH): 
mlz (M + H)+ 1023 
Conjugate 5D 
OI-I (1.2~ Ala 13) (1.25~ Ala 13) (1.35-1.6; Arg, Lys 13, x, Lys 0) (2.3: L) (2.7-2.8: 
Cys~, Lys E, L) (2.9~ L) (3.1~ Arg 0) (3.4; Ala a) (4.2; Ala, Arg, Lys a) (4.4--+.5: 
Ala, Cys, a, L) (7.0-7.3; Arg guanidinium) (7.6; Arg NH (SC)) (7.8: Lys NH 
(SC)) (7.9-8.5; Ala, Arg, Cys, Lys NH, Ar CH) (9.7; NH)~ mlz (M + Ht 1151 
Peptide 6 
OH (1.25; Ala Jl) (1.4; Ala Jl) (1.5-1.7; Arg ,Lys Jl, X, Lys 0) (2.6: Asn Jl ) (275; 
Lys E) (2.8; Cys Jl) (3.0; Arg 0) (3.9; Ala a) (4.1: Ala a) (4.2: Arg, Lys a) (44. 
Cys) (4.5: Asn) (7.0-7.3 Arg guanidinium) (7.5: Arg NH (SCll (7.8: Lvs NH 
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(SC)) (7.9~ Ala NH) (8.1~ Ala, Arg, Lys NH) (8.3; Cys NH) (8.5; Asn NH); m z 
(M + Ht 817 
Conjugate 6A 
8H (1.2~ Ala f3) (1.5-1.7~ Arg, Lys f3, x, Lys 8) (2.4; L) (2.6; Asn f3 ) (2.8; Cys 
f3,Lys E) (3.1; Arg 8, L) (3.4; L) (4.1-4.3~ Ala, Arg, Cys, Lys a) (4.6; Asn a) (7.0-
7.3~ Arg guanidinium) (7.5~ Arg NH (SC)) (7.7; Lys NH (SC)) (7.9-8.3; Ala, Arg, 




(1.2~ Ala f3) (1.3~ Ala f3) (1.5-1.7; Arg, Lys f3, x, Lys 8) (2.3-2.4; L) (2.6; Asn 
f3) (2.7-2.8~ Cys f3, Lys E, L) (2.9-3.1; Arg 8, L) (3.3; L) (4.1; Ala a) (4.2-4.4; Ala, 
Arg, Cys, Lys a, L) (4.5~ Asn a) (7.1-7.3; Arg guanidinium) (7.6; Arg NH (SC)) 
(7.8; Lys NH (SC)) (8.0-8.3; Ala, Arg, Asn, Cys, Lys, ArCH) (9.7; NH); m1z (M 




(1.2~ Ala f3) (1.3; Ala f3) (1.3-1.6; Arg ,Lys f3, X, Lys 8) (2.7-2.8; Cys ~, Lys E) 
(3.1 ~ Arg 8) (3.9~ Ala a) (4.1; Ala a) (4.2; Arg, Lys a) (4.4; Cys a) (7.1-7.3 Arg 
guanidinium) (7.6~ Arg NH (SC)) (7.75; Lys NH (SC)) (7.8; Ala NH) (8.0-8.5: 
Ala, Arg, Cys, Lys NH); m1z (M + Ht 831 
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Conjugate 7 A 
8B (1.2; Ala (3) (1.4-l.6; Arg, Lys (3, X, Lys 8) (2.3-2.4; L) (2.7-2.8; Cys (3, Lys Eo 
L) (3.1; Arg 8, L) (3.4; L) (4.1-4.5; Ala, Arg, Cys, Lys a) (7.1-7.3: Arg 
guanidinium) (7.6; Arg NH (SC) (7.7-8.3; Lys NH (SC), Ala, Arg, Cys, Lys NH, 
ArCH); mJz (M + Ht 1179 
Conjugate 7D 
8B (l.2; Ala (3) (1.25; Ala (3) (1.4-l.6; Arg, Lys (3, X, Lys 8) (2.3; L) (2.7-2.8; Cys 
(3, Lys E, L) (2.9-3.1; Arg 8, L) (4.1-4.5; Ala, Arg, Cys, Lys a, L) (7.0-7.3; Arg 
guanidinium) (7.6; Arg NH (SC)) (7.7; Lys NH (SC)) (7.8-8.5; Ala, Arg, Cys, Lys 




(l.2; Ala (3) (l.3; Ala (3) (l.5-1.7; Arg, Lys (3, X, Lys 8) (2.6; L) (2.7-2.8; Cys 
(3, Lys E, L) (3.1; Arg 8, L) (3.9; Ala a) (4.2; Ala) (4.3; Arg, Lys a) (4.4; Cys a) 
(7.0-7.4; Arg guanidinium) (7.7; Arg NH (SC) (7.9-8.2; Lys NH (SC), Ala, Arg, 




(1.2; Ala (3) (l.5-l.6; Arg, Lys (3, X, Lys 8) (2.2-2.5; L) (2.8; Cys (3, Lys E, L) 
(3.0; Arg 0, L) (3.5; L) (4.1-4.5; Ala, Arg, Cys, Lys a) (7.1-7.3: Arg guanidiniumJ 
(7.6; Arg NH (SC)) (7.7; Lys NH (SC)) (7.9; Ala NH) (80-83; Ala, Arg, Cys. 




8H (1.2; Ala (3) (1.25; Ala (3) (1.35; Ala (3) (l.4-1.6; Arg ,Lys (3, X, Lys 8) (2.75: 
Lys £) (2.8; Cys (3) (3.1; Arg 8) (3.9; Ala a) (4.2; Ala a) (4.3; Arg, Lys a) (4.4: 
Cys a) (7.0-7.3 Arg guanidinium) (7.5; Arg NH (SC)) (7.7; Lys NH (SC)) (7.8-
8.4; Ala, Arg, Cys, Lys NH); mlz (M + Ht 689 
Conjugate 8A 
8H (1.25; Ala (3) (1.4-1.6; Arg, Lys (3, X, Lys 8) (2.4; L) (2.7-2.8; Cys (3, Lys E, L) 
(3.1; Arg 8, L) (3.4; L) (4.1-4.5; Ala, Arg, Cys, Lys a) (7.2-7.4; Arg guanidinium) 
(7.5; Arg NH (SC)) (7.7-8.3; Lys NH (SC), Ala, Arg, Cys, Lys NH, ArCH) (9.8; 
H); mlz (M + Ht 1037 
Conjugate 8D 
8H (1.1; Ala (3) (l.2; Ala (3) (l.3-l.5; Arg, Lys (3, X, Lys 8) (2.3; L) (2.7-2.8; Cys 
(3, Lys £, L) (3.1; Arg 8, L) (3.4; L) (3.5; Ala a ) (4.15; Ala) (4.2: Arg, Lys a) 
(4.3; Ala a) (4.4; Cys a) (7.0-7.3; Arg guanidinium) (7.5; Arg NH (SC)) (7.7-8.3; 
Lys NH (SC), Ala, Arg, Cys, Lys NH, ArCH); mlz (M + Ht 1165 
6.4 DNA-Drug Interactions 
All glass apparatus used in these studies were silanised with dichloromethylsilane. 
washed with methanol followed by water and dried at room temperature before 
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use. The volumetric glassware used was of grade A specification. All volumes 
less than 1.0mI were measured using Hamilton precision glass syringes. The 
water used was either freshly prepared double distilled or Millipore water. 
Tris buffers (O.008M Tris hydrochloride; pH 7.2) with either sodium chloride 
concentrations of O.5M or O.05M were prepared. The former was used in the 
determination of the isosbestic points and the latter was used in the fluorescence 
and thermal denaturation studies. Stock peptide conjugate solutions were 
prepared in 1-2% v/v DMSO in the appropriate Tris buffer. The DNA solution 
was prepared by dissolving calf thymus DNA in each of the buffers to give a 
solution of approximately 2mg mI- l . The concentration of DNA, expressed in 
terms of the molar concentration of DNA phosphate was determined at ~60nm 
using E = 6600M1cm-1• All solutions were protected from light and stored at .f°C. 
6.4.1 Spectroscopic Studies 
Calf thymus DNA in Tris buffer (5 x 10-3M) was added to eight 10ml volumetric 
flasks containing the peptide conjugate (1.5 x 10-5) in the same buffer so that the 
DNA:drug concentration varied from 0 to 15:1. After each addition the solutions 
were made up to volume using buffer, gently shaken and left to stand for one 
minute. The spectra of the solutions were recorded superimposed using a Perkin 
Elmer UV NIS Spectrophotometer against a buffer blank over the range of the 




6.4.2 Fluorescence Studies 
Aliquots (6 x 10J!l, 5 x 20J!l, 6 x 40J!1, 6 x 100J!l) of ethidium bromide so lution (2 
x 10-5M) were added sequentially to a 3.0m! volume of each of the following 
solutions i) 2 x 10-5M calf thymus DNA in Tris buffer, pH 7.2: ii) 2 x 10-5M calf 
thymus DNA and 2 x 10-6M of peptide conjugate in buffer; iii) 2 x 10-6M peptide 
conjugate in buffer and iv) buffer. After each addition the solution was gently 
stirred and allowed to stand for one minute. The fluorescence intensity was then 
determined at 25°C in triplicate using a Perkin Ehner LS-5 Luminescence 
Spectrometer at "-emission 596nm ("-excitation 479nm). The mean fluorescence 
intensities were corrected for changes in vo lume and the above experiment was 
repeated twice. 
6.4.3 Thermal Denaturation Studies 
Calf thymus DNA (0.2m!; 4.6 x 10-3M) in Tris buffer, pH 7.2 was added to an 
appropriate volume of peptide conjugate (9 x 10-6M) in 3ml of the same buffer 
such that the DNA to drug ratio was 10: 1. The volume was made up to 10ml with 
Millipore water. The changes in absorbance of the DNA-conjugate solution were 
recorded at 260nm as the temperature was raised from 60 to 105°C (0.5°Cmin-
l
) 
in a Perkin Elmer Spectrophotometer 552 fitted with a temperature programmer. 
The above experiment was repeated three times for each conjugate. 
185 
Chapter 6 
6.5 Structural Analysis 
6.5.1 NMR Spectroscopic Studies 
Spectra were acquired on a Broker AC 250 MHz spectrometer equipped with an 
Aspect 3000 computer. By use of standard methods a set of 2-dimensional 
spectra were accumulated in phase incrementation: Double Quantum Filtered 
Phase Sensitive COSY and NOESY - with mixing times in the range of 100-
600ms. Data were accumulated with 16 transients and 4 dummy transients in 
2048 data points in the second time domain (tz) and in 1024 in the first one (t1). 
Spectra were recorded in both DMSO and TFE. 
6.5.2 Circular Dichroism Studies 
The circular dichroism of the peptides was measured with a Jobin-Yvon CD6 
spectrophotometer. All experiments were performed in the UV region (180-
270nm) at 25°C, using 0.5mm path length quartz cells. 
6.5.3 Molecular Modelling Studies 
Studies were conducted on the peptides and their interaction with the DNA AP-l 
site in an aqueous environment. The structures in each case were minimised using 
an RMS first derivative of O.OOlkcal/mol, which was achieved typically with 
5000 iterations using Insight and Discover software (Biosym Technologies, San 
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